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ABSTRACT
The Expression and Function of Hypoxia inducible factor-1α in Human Melanoma
By Sandeep S. Joshi
Hypoxia inducible factor-1α (HIF-1α) protein, a key regulator of oxygen homeostasis, is
stabilized under hypoxia and degraded under normal oxygen tension. Here, the human
melanoma cells were found to express an elevated amount of HIF-1α mRNA and protein
relative to normal human melanocytes under normoxic conditions. The amount of HIF-1α
expressed is roughly correlated with the stage of melanoma from which the cell line was
established. In addition, a splice variant mRNA of HIF-1α785 is expressed at higher levels
than full-length HIF-1α mRNA in the more aggressive melanoma cells. This splice variant
lacks part of the oxygen regulation domain. Ectopic expression of HIF-1α in a radial growth
phase melanoma cell line increased their ability to form colonies in soft agar and their ability to
invade and migrate through Matrigel.

Conversely, knockdown of HIF-1α expression in

metastatic melanoma cell line decreased their ability to form colonies in soft agar as well as
their ability to invade and migrate through Matrigel. Further, it has been shown that the
ERK1/2 MAPK pathway is probably not involved in the expression of HIF-1α under normoxic
conditions. In addition, the normoxic expression of HIF-1α directly regulates the
micropthalamia-associated transcription factor (MITF) mRNA and protein expression in
human metastatic melanoma cell line. There was clear shift in MITF expression from MITF-M,
a specific isoform in melanocytes, to the predominantly MITF-A in metastatic melanoma. The
MITF-A promoter contains two hypoxia response elements while none were found in the
MITF-M promoter region. Reporter gene and chromatin immunoprecipitation assays confirmed
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that HIF-1α directly binds and transactivates the MITF-A promoter in metastatic melanoma
cells.

Knockdown of MITF expression in metastatic melanoma cell line decreased their

viability through induction of apoptotic pathways. Overall data suggest that increased
normoxic expression of HIF-1α contributes to some of the malignant properties of melanoma
and increases its importance as a therapeutic target. Further, HIF-1α activates the expression of
MITF-A whose expression contributes to the survival of metastatic melanoma cells.
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CHAPTER ONE
INTRODUCTION
Melanoma
Melanoma originates from melanocytes and is the most deadly form of all skin cancers.
Melanocytes are responsible for skin pigmentation and are situated at the base of the epidermis.
The melanin produced by the melanocytes protects skin against the sun’s harmful rays. The
incidence and death due to melanoma over the past decade has increased more rapidly than any
other type of cancer (Melanoma Research Foundation). The increased incidence of melanoma is
also associated with the type of human skin coloration and environmental sun exposure. The
highest incidence of melanoma is found among the fair skin, red haired individuals that reside in
the sun-belt area of Australia (Bowden, 2004). Melanoma, if diagnosed early can be surgically
removed, however metastatic melanoma is notoriously resistant to chemotherapies and the
median lifespan of these patients is less than 12 months (Melanoma Research Foundation).
The Breslow and Clark number are often used to predict prognosis of melanoma
patients. Breslow’s measurements are based on thickness of a melanoma tumor while Clark’s
measurements are based on how deep the tumor has penetrated into the layers of skin. The
greater the thickness or deeper the penetration worsen the prognosis of melanoma patients.
According to the widely respected Clark model of tumorigenesis, melanoma development and
progression include several clinical stages. These include 1) common nevus, 2) melanocytic
dysplasia, 3) radial growth phase (RGP), 4) vertical growth phase (VGP) and 5) metastatic
melanoma (MM). (Figure 1.1). (Clark et al., 1984; Meier et al., 1998)
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Figure 1.1: Melanoma development and progression. The model, developed by Drs. Clark,
Elder, and Guerry, implies that melanoma commonly develops and progresses in a sequence of
steps from nevic lesions which can be histologically identified in approximately 35% of cases.
Thus, melanoma may also develop directly from normal (and precursor cells). The roles of
melanocyte stem cells, melanoblasts (immature melanocytes) in melanogenesis remain poorly
defined. Cells from lesions show persistence but non-tumorigenic lesions tend to disappear
through apoptotic or differentiation pathways which are also poorly defined (Meier et al., 1998).
For the melanoma to develop the normal melanocyte cells needs to aquire characteristics such
as clonal expansion, avoiding the senescence and escape of apoptosis (Bennett, 2008).

Melanoma commonly develops and progresses in a sequence of steps from nevic lesions
which can be histologically found in approximately 35% of cases (Meier et al., 1998). However,
melanoma may also develop from normal melanocyte cells through various genetic changes.
According to Bennett’s model, probably no one particular genetic change is crucial in
melanoma genesis, but rather any set of changes generating a specific set of biological outcomes
is important. The biological outcomes that are involved in generation of melanoma from normal
melanocytes include; 1) initiation of clonal expansion 2) avoiding the melanocyte senescence,
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and 3) escape from apoptosis. The lesions with changes in step one and two are thought to grow
only in epidermis, like RGP melanomas.

RGP is an early stage melanoma that grows

horizontally on the skin surface without undergoing differentiation. The changes leading to
suppression of apoptosis might be an essential step for further progression of RGP to the VGP
stage (Bennett, 2008). VGP cells have the ability to invade and grow vertically into the dermis.
This stage shows maximum cytogenetic abnormalities suggesting considerable genetic
instability. Additional genetic changes are necessary for the transition from VGP to metastatic
melanomas. Micro-environmental factors such as cell-matrix and cell-cell signaling could be
critical for inducing metastatic phenotype. Metastatic cells have the ability to migrate to distant
organs and form tumors when the microenvironment is favorable. (Meier et al., 1998)
Recently, through various genetic and molecular studies several key molecules that play
a role in melanoma development have been identified. The major genetic alteration found in
approximately 60% of human melanomas is BRAF (Davies et al., 2002; Rodolfo et al., 2004).
This mutation leads to constitutive activation of the extracellular signal-regulated kinase /
mitogen activated protein kinase (ERK/MAPK) pathway. Some melanomas (20%) have an NRAS mutation which also leads to activation of the ERK/MAPK pathway (Rodolfo et al., 2004;
Eskandarour et al., 2004). These mutations are mutually exclusive i.e., melanomas have one or
the other, but not both at the same time. A paradox is that these mutations are also found in
nevi. Thus, additional changes are required for the development of melanoma. In addition to
activation of an oncogene, the loss of several tumor suppressor genes has been observed in
melanoma. The various familial melanomas that are caused due to mutations in the tumor
suppressor genes include cell cycle regulators such as CDKN2A and CDK4. Mutation in these
genes leads to an increase in cell cycle progression and thereby an increase in cell growth. The
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CDKN2A mutations appear in 25-40% of familial melanomas (Levy et al., 2006). Another
tumor suppressor that is found to be mutated in ~30% of melanomas is PTEN (Celebi et al.,
2000). The loss of PTEN enzyme activity leads to activation of the PI3K pathway, which
permits cells to divide uncontrollably. Although, significant progress has been made in
understanding the mechanisms responsible for melanoma development, the key regulators
involved in the advancement of disease are yet to be determined.
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Hypoxia inducible factor-1 (HIF-1)
Hypoxia inducible factor-1 (HIF-1) is the most important factor involved in sensing and
adapting cells to respond to a decrease in O 2 levels. Hypoxia, a state in which O 2 demand
exceeds the supply, induces acute, as well as long term, physiological responses such as
erythropoiesis, neovascularization and glycolysis. These processes increase the O 2 supply to the
hypoxic region and active adaptive metabolic pathways such as glycolysis which is the only
metabolic pathway that can produce energy in the absence of oxygen (Lisy and Peet 2008;
Semenza 2003). The genes that are induced by hypoxia include erythropoietin (EPO), vascular
endothelial growth factor (VEGF), and certain glycolytic enzyme genes containing unique
promoter DNA sequences called hypoxia response elements (HRE) (Semenza and Wang 1992).
These DNA elements were found to bind the heterodimeric transcription factor, HIF-1 (Wang
and Semenza 1995).
HIF-1 a master regulator of oxygen homeostasis is a heterodimeric protein complex
consisting of a constitutively expressed HIF-1β subunit and a HIF-1α subunit whose expression
is highly regulated. HIF-1α expression is regulated at both the transcriptional and translational
level. Transcriptional regulation is O 2 -independent, while post-translational regulation is O 2 dependent. Over 70 HIF-1 regulated genes have been identified and many of these genes are
involved in crucial aspects of tumor biology including angiogenesis, cell survival, glucose
metabolism and invasion (Semenza 2003; Mazure et al., 2004; Hampton-Smith and Peet, 2009).
HIF-1 belongs to the PER-ARNT-SIM (PAS) subfamily of the basic-helix-loop-helix
(bHLH) family of transcription factors. The HIF-1 family consists of various isoforms such as
HIF-1α, HIF-2α, and HIF-3α which heterodimerizes with HIF-1β also known as aryl
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hydrocarbon receptor nuclear translocator (ARNT). HIF-1α and HIF-2α are closely related both
structurally and functionally. HIF-2α is also known as endothelial PAS domain protein 1
(EPAS1) due to its selective expression in endothelial cells. HIF-3α is also known as Inhibitory
PAS Domain protein (IPAS) due to lack of a transactivation domain that is present in factors 1α
and 2α. It therefore act as a negative regulator of hypoxia-inducible gene expression (Jang et al.,
2005; Weidemann and Johnson, 2008).
The HIF-1α and β subunits are similar in structure. Both contain a bHLH and a PAS domain at
the N-terminus that are required for DNA binding and dimerization respectively. The bHLH
domains are found in specific DNA- binding proteins that act as transcription factors and are
usually 60-100 amino acids long. bHLH regions form homo- and heterodimers. The PAS domain
was named after three proteins that the domain occurs in: Per- period circadian protein, Arntaryl hydrocarbon receptor nuclear translocator protein and Sim- single-minded protein
(Hogenesch and Bradfield, 2010). The C-terminus of HIF-1α and β contains a transactivation
domain (TAD) where transcriptional co-regulators bind.
In addition to these domains, the C-terminal half of the HIF-1α subunit contains an
oxygen-dependent degradation domain (ODDD) that confers oxygen-dependent instability. The
ODDD domain in HIF-1α is a highly regulated domain that is subject to various posttranslational

modifications,

including

hydroxylation,

acetylation,

sumoylation

and

phosphorylation. These modifications are necessary to inhibit HIF-1α responsive genes in
normoxia either by inducing protein degradation or by inhibiting its activity. HIF-1α also
contains two separate transactivation domains (N-TAD and C-TAD). N-TAD is present within
the ODDD and between N-TAD and C-TAD lies an inhibitory domain (ID) that is a negative
regulator of TAD (Figure 1.2) (Jiang et al., 1997; Weidemann and Johnson, 2008).
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Figure 1.2: Domain structure of HIF-1α and targeted residues involved in its regulation.
HIF-1α possesses bHLH and PAS domains which are involved in dimerization with HIF-1β
and DNA binding. The HIF-1α subunit contains two TAD, the N- and the C- TADs. The NTAD lies within the ODDD. The ODDD regulates the stability of HIF-1α via recognition, by
the von Hippel-Lindau E3 ubiquitin ligase (pVHL), of the hydroxylation state of Proline402
and/or Proline564 residues. This hydroxylation is catalyzed by the enzyme PHD (prolyl
hydroxylase domain protein). Acetylation of the Lys532 residue by the ARD1 acetyltransferase
also favors interaction with pVHL. The hydroxylation state of the Asparate803 residue, by the
enzyme FIH-1 (factor inhibiting HIF-1) inhibits binding of p300/CBP, a HIF-1α co-activator.
S-nitrosation of Cys800, in the C-TAD, also promotes HIF-1 transcriptional activity. Three
consensus sequences at Lys-391, -477, and -532 may be modified by SUMO. The domain from
531 to 826 has been shown to be phosphorylated (Mazure et al., 2004)

Factors regulating HIF-1α protein stability
PHDs

PHDs are prolyl hydroxylase enzymes with the isozymes PHD1, PHD2 and PHD3 being
the most studied and well characterized (Masson et al., 2001). PHD1 is found specifically in the
nucleus, PHD2 in the cytoplasm and PHD3 is found throughout the cell. In the presence of
oxygen, 2-oxoglutarate and ascorbate, PHD, an iron-dependent enzyme, converts proline
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residues to hydroxyproline. Proline residues (Pro402 and Pro564) within the ODDD of HIF-1α
protein and have been shown to be hydroxylated (Epstein et al., 2001; Smith et al., 2010). Upon
hydroxylation of these proline residues in normoxic conditions, the HIF-1α protein is subjected
to ubiquitin based proteasomal degradation. PHD enzymes are defined as oxygen sensors
because their activity depends on the oxygen concentration in the cell. Oxygen concentrations
also control the PHD mRNA levels. Since PHD enzymes are iron-dependent, iron chelators like
desferrioxamine (DFO) and the iron antagonist cobalt chloride (CoCl 2 ) are used as hypoxia
mimetic drugs to stabilize HIF-1α protein. HIF-1α can also control its own activity by regulating
the expression of PHD2 (Mazure et al., 2004).

pVHL

Von Hippel-Lindau (VHL) is a tumor suppressor gene; a germline mutation in this gene
is the basis of a rare familial VHL syndrome (Kaelin 2002). This syndrome induces a
predisposition to a variety of malignant and benign tumors, in particular clear-cell renal
carcinomas, and cerebellar hemangioblastomas (Friedrich 2001; Smaldone and Maranchie,
2009). The protein encoded by this gene is a component of the E3 ubiquitin-protein ligase
complex that targets proteins for ubiquitin based proteasomal degradation (Lisztwan et al.,
1999). This protein is involved in the ubiquitination and degradation of proline hydroxylated
form of HIF-1α protein (Maxwell et al., 1999; Ohh et al., 2000; Weidemann and Johnson, 2008)
(Figure 1.3). The multiple mutations or downregulation of VHL leads to accumulation of HIF-1α
in cells grown under normoxic conditions (Hughston et al., 2003).
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Figure 1.3: Oxygen dependent regulation of HIF-1α. Oxygen dependent regulation of HIF1α is post-translational. HIF-1α protein is constitutively expressed in all cells. In normal
oxygen tension HIF-1α protein is hydroxylated and acetylated by PHD2 and ARD1 enzymes
respectively. Upon hydroxylation and acetylation, VHL an ubiquitin ligase enzyme binds to
HIF-1α protein that leads to polyubiquitination and proteasomal based degradation. However,
in hypoxic condition these enzymes PHD2 and ARD1 cannot hydroxylate or acetylate HIF-1α
protein respectively. Thereby, VHL cannot bind to HIF-1α protein and making it stable under
hypoxic conditions. Upon stabilization HIF-1α protein translocates to the nucleus
heterodimerizes with HIF-1β and transactivates genes that play role in adapting cells in
hypoxic stress.

ARD1

Arrest-defective-1 protein (ARD1) is an acetyltransferase enzyme that is responsible for
acetylation of HIF-1α protein. lysine532 within the ODDD of HIF-1α is the target for acetylation.
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Upon acetylation of lysine532 which is in close proximity to hydroxyproline564, the pVHL protein
is recruited and results in the ubiquitination and proteasomal degradation of HIF-1α (Jeong et al.,
2002). HIF-1α785 splice variant of a full length HIF-1α is missing the segment encoded by exon
11 and thus, ARD1 cannot acetylate Lysine532. Lack of this acetylation leads to less stable
interactions between the protein and VHL, and thereby less proteasomal based degradation
(Chun et al., 2003). Thus, HIF-1α785 is thought to be more stable under normoxic conditions
relative to full length HIF-1α. ARD1 activity is not known to be dependent on oxygen and,
therefore, the HIF-1α protein acetylation occurs under both normoxic and hypoxic condition.
Other than ARD1, the acetylation HIF-1α is also regulated by histone acetyltransferases (HATS)
and deacetylation by histone deacetylases (HDACs) (Ellis et al., 2009).

Nitric oxide (NO)
NO has also been shown to increase HIF-1α protein instability. NO does so by increasing
intracellular oxygen resulting in increased PHD-mediated proline hydroxylase-dependent
degradation of the HIF1α protein (Mazure et al., 2004; Dehne and Brune, 2009).
Factors regulating HIF-1α protein activity
Factor inhibiting HIF-1(FIH-1)

FIH-1, like the PHDs, is an iron-dependent hydroxylase enzyme but instead of proline
residues it is responsible for hydroxylation of asparagine803 within the HIF-1α protein. FIH-1
does not influence HIF-1α protein stability, but instead inhibits the binding of co-activator
p300/CBP at the C-TAD region and thereby represses HIF-1α transcriptional activity (Mazure et
al., 2004; Webb et al., 2009).
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Mitogen activated protein kinase (MAPK)
Stabilization of HIF-1α under hypoxic conditions results in phosphorylation by the
MAPK in vivo as well as in vitro (Richard et al., 1999). Moreover, phosphorylation of HIF-1α is
associated with increased transcriptional activity by enhancing the interaction between p300 and
the C-TAD (Sang et al., 2003).

Small ubiquitin-related modifier (SUMO)

SUMO is a member of the ubiquitin-like protein family. The process for SUMO
modification is similar to ubiquitination. However, SUMO does not target the protein for
degradation. Instead sumoylation regulates protein localization and regulates the activity of a
transcription factor usually in the negative direction. HIF-1α is shown to undergo sumoylation by
the sumo E3 ligase, RanBP2, in vitro at Lys391, Lys477 and Lys532 (Mazure et al., 2004). The
physiological effect of HIF-1α sumoylation is still under investigation.
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Figure 1.4: Oxygen independent regulation of HIF-1α. Oxygen independent regulation of
HIF-1α is transcriptional. It occurs mainly in growing cells and is regulated by growth
signaling pathways. Growth factor binding to a cognate receptor tyrosine kinase activates the
ERK-MAPK and PI3-AKT pathways. Activation of these pathways by growth factors leads to
HIF-1α mRNA synthesis and thereby increasing the HIF-1α protein levels.

Oxygen-independent regulation of HIF1α
The oxygen-independent regulation of HIF-1α is at the transcriptional level mainly
through growth-factor stimulation (Figure 1.4). The growth-factor mediated increase in HIF-1α
mRNA is cell type specific, while the hypoxia mediated increase of HIF-1α levels occurs in all
cell types (Semenza 2003). Moreover, the hypoxic regulation of HIF-1α expression is due to a
decrease in HIF-1α protein degradation while growth-factors, cytokines and other signaling
molecules stimulate HIF-1α mRNA expression through activation of phosphatidylinositol 3-
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kinase (PI3K) or mitogen-activated protein kinase (MAPK) (Fukuda et al., 2002; Zhong et al.,
2000). Among HIF-1α’s target genes are various growth factors such as insulin-like growth
factor (IGF2) and transforming growth factor (TGF-α). These growth factors upon binding to
their respective receptors on cell surface could activate signal transduction pathways involved in
stimulating HIF-1α expression, thereby setting up a positive feedback loop (Feldser et al., 1999;
Krishanmachary et al., 2003).

Figure 1.5: Splice variants of HIF-1α. HIF-1α consist of various isoforms; full length (FL),
785, 736, 557, 516 and 417 that originate due to splicing. The longest HIF-1α isoform consist
of 826 amino acids and contains all the conserved domains and has 14 exons. HIF-1α785 is
similar to FL but lacks exon 11. The missing exon 11 contains Lys532, a critical component of
ODDD, which is responsible for acetylation by ARD1 leading to interaction between HIF-1α
and VHL. This interaction directs for ubiquitation based proteasomal degradation under
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normoxic condition. Thus HIF-1α785 is thought to be more stable than full length HIF-1α
under normoxic conditions (Lee et al., 2004).

HIF-1α isoforms
HIF-1α consists of various isoforms; full length (FL), 785, 736, 557, 516 and 417 that
originate due to alternate splicing (Figure 1.5). The longest HIF-1α isoform consists of 826
amino acids and contains all the conserved domains described above. FL is ~120kDa and has 14
exons. HIF-1α785 is similar to FL but lacks exon 11 and is ~91kDa. The missing exon 11 contains
lys532, a critical component of ODDD, which is responsible for acetylation by ARD1 leading to
interaction between HIF-1α and VHL. This interaction directs ubiquitation-dependent
proteasomal degradation under normoxic conditions. Thus, HIF-1α785 is thought to be more
stable than full length HIF-1α under normoxic conditions (Lee et al., 2004).
HIF-1α736 lacks exon 14 which carries C-TAD and it is thought to be a tumor suppressor.
It is 3 times less active than FL HIF-1α. The 557 isoform lacks exon 12 and is also named as
HIF-1αZ. It is regulated by zinc. It does not contain a nuclear localization signal (NLS) and is
known to play a dominant negative role by sequestering HIF-1β in the cytosol. HIF-1α516 is
similar to 557, but, in addition it is missing the TAD. HIF-1α417 is the shortest isoform and is
missing the ODDD and TAD domains. It heterodimerize with HIF-1β and uses HIF-1β’s TAD to
initiate transcription of target genes (Lee et al., 2004).
HIF-1α inhibitors
GL331 is a potent inhibitor of tumor-induced angiogenesis in lung cancer cells through
inhibition of VEGF. The underlying mechanism responsible for angiogenic inhibition by GL331
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is through downregulation of HIF-1α expression by transcriptional repression (Chang et al.,
2003).

Echinomycin (NSC-13502) is a small-molecule known to bind DNA in a sequencespecific fashion. NSC-13502 inhibited the binding of HIF-1α and HIF-1β proteins to the HRE
present in the promoter region of VEGF; echinomycin did not affect the AP-1 / NF-kB binding
to the promoter regions of their respective target genes. Accordingly, NSC-13502 inhibited
hypoxic induction of luciferase in U251-HRE cells and VEGF mRNA expression in U251 cells
(Kong D et al., 2005). Other small molecules like synthetic pyrrole-imidazole polyamide
(Olyenuk et al., 2004) and DJ12 (Jones et al., 2006) are also found to inhibit HIF-1α DNA
binding to endogenous promoters.

TX-402, a potent hypoxia-selective cytotoxic agent, was shown to reduce the expression
of VEGF and glucose transporter type 3 (GLUT-3) under hypoxic conditions. The mechanism
appears to involve suppression of HIF-1α mRNA and protein levels (Nagasawa et al., 2003). The
National Cancer Institute Diversity Set of 2000 compounds was screened for potential HIF-1α
inhibitors. NSC-134754, a semisynthetic analogue of emetine (a natural alkaloid) and NSC643735, a structural analog of actinomycin D aglycone, were both shown to have HIF-1
inhibitory effects. NSC-134754 inhibited hypoxia-induced HIF-1 activity, Glut-1 expression and
HIF-1α protein expression. Both compounds were able to inhibit growth factor-induced HIF-1α
protein expression (Chau et al., 2005).

The dietary component curcumin has been shown to inhibit hypoxia-stimulated in vitro
angiogenesis and to downregulate HIF-1α and VEGF mRNA expression in endothelial cells (Bae
et al., 2006). Additional dietary constituents such as quercetin, epigallocatechin gallate (EGCG),
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resveratrol, inositol, etc. have been reported to affect HIF-1α expression or function in different
types of cancer cells (Zang et al., 2006; Wu et al., 2008; Gu et al., 2009)

Physiological role of HIF-1

HIF-1 is functional in all mammalian cell types while the HIF-1–VHL–PHD system is
fully conserved from D. melanogaster to C. elegans to H. Sapiens (Wiesener and Maxwell
2003). At the cellular level when oxygen levels drop, the oxygen sensor stimulates a signal
which is responsible for increased expression of HIF-1α. The HIF-1α-β dimer then transactivates
genes including those encoding glycolytic enzymes for anaerobic metabolism, VEGF for
angiogenesis, inducible nitric oxide synthase and hemoxygenase-1 for the production of
vasodilators, EPO for erythropoiesis and tyrosine hydroxylase for dopamine production to
increase breathing (Figure 1.6). These gene products help cells to survive under a low oxygen
supply and act to restore normal oxygen levels (Guillemin and Krasnow 1997; Semenza, 2008).
Most of these genes are stimulated in all hypoxic cells, However, some genes like EPO are cell
type specific and thus require tissue specific regulators. The orphan nuclear receptor hepatic
nuclear factor-4 is thought to be a tissue specific regulator that works in association with HIF-1
to regulate EPO expression in the liver and kidney (Galson et al., 1995).
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Figure 1.6: HIF-1α targets involved in different physiological processes. HIF-1α protein on
stabilization heterodimerizes with HIF-1β and target various genes that are involved different
physiological processes. HIF-1α transactivated genes such as gycolytic enzymes involved in
anaerobic metabolism, VEGF involved in angiogenesis, erythropoietin involved in
erythropiesis, iNOS and HO-1 involved in vasodilation and tyrosine hydroxylase involved in
increased breathing (Guillemin and Krasnow 1997).
HIF-1α is required for embryonic development. In the homozygous HIF-1α-null mouse
embryonic development is arrested at day 8, and the embryos are dead by day 10 due to cardiac
malformations, vascular regression and mesenchymal cell death (Iyer et al., 1998; Kotch et al.,
1999). The heterozygous-null (HET) mice develop normally and are indistinguishable from wild
type; however they have impaired responses for hypoxia and ischemia (Yu et al., 1999). The
HET mice revealed that HIF-1α plays a critical role in the pathophysiology of hypoxia-induced
pulmonary hypertension. The ventilator response to chronic hypoxia, mediated through the
carotid body, was lost in HET mice. These results suggest that HIF-1α is required for carotid
body function. HIF-1α is also required for the cardiovascular and ventilatory response to
intermittent hypoxia (Semenza 2006).
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HIF-1 protein stabilization has been detected in certain ischemic conditions. In mice with
oxygen-induced ischemic retinopathy, HIF-1α levels were shown to be increased in the retina
(Ozaki et al., 1999). Brain ischemia also results in increased HIF-1α transcriptional activity.
HIF-1α and HIF-1β protein levels were also significantly increased after intraperitoneal injection
of CoCl 2 (Bergeron et al., 2000). The kidney demonstrates a marked potential for upregulation
of HIF, but accumulation of HIF-1α and HIF-2α is selective with respect to cell type, kidney
zone, and experimental conditions. HIF-1α was mainly induced in tubular cells, including
proximal segments with exposure to anemia/carbon monoxide, in distal segments with CoCl 2
treatment, and in connecting tubules and collecting ducts with both stimuli plus renal ischemia.
HIF-2α was not expressed in tubular cells but was expressed in endothelial cells of a small subset
of glomeruli, in peritubular endothelial cells and in fibroblasts. In addition, upregulation of HIF1α was also shown to be associated with the renal ischemia (Rosenberger et al., 2002). The
functional role of this activation is still under investigation. However, since stabilization of HIF1 leads to angiogenesis and hypoxia-induced metabolic adaptation, this adaptive response should
prevent excessive death of kidney cells (Wiesener and Maxwell, 2003).

HIF-1 has generated a new hope to counteract neurodegenerative diseases. The cerebral
ischemic stroke leads to various neurological dysfunctions due to reduction in blood supply that
provides glucose and oxygen for the normal brain function (Correia and Moreira, 2010). The
activation of HIF-1 through hypoxia-mimetic agents like CoCl 2 and DFO has shown to provide
protection against cereberal ischemic damage (Baranova et al., 2007). The underlying
mechanism responsible for HIF-1-mediated cytoprotection is thought to be due to HIF-1-indued
EPO expression. A clinical trial conducted in 13 patients by intravenous administration of
recombinant EPO showed marked reduction in the infarct size compared to control (Ehrenreich
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et al., 2002). Moreover, VEGF another HIF-1α target induced by hypoxia leads to growth of
new vessels after cerebral ischemia, thereby minimizing the detrimental effects of cereberal
ischemia (Marti et al., 2000).

Alzheimer’s disease (AD) is a progressive and fatal disease that is characterized by
neuronal loss, cognitive dysfunction and dementia. The pathological lesions found in AD
patients consist of plaques composed of amyloid-β (Aβ) peptides and intracellular neurofibrillary
tangles containing hyperphosphorylation of tau protein (Correia and Moreira, 2010). Glucose
metabolism and uptake is required for normal brain function, and this process is highly impaired
in AD patients. Accumulating evidence suggests that impaired glucose uptake and metabolism is
the leading cause and not the consequence of the disease (Hoyer 2004). Recently, Liu et al
(2008) reported that the glucose transporters GLUT-1 and GLUT-3 were strongly downregulated
in the brain of AD patients. In addition, he found HIF-1α protein was also decreased in these
patients. In a single clinical study conducted in AD patients, by intramuscular administration of
DFO, an iron chelator and HIF-1 inducer, slowed cognitive decline by more than 50% in 2 years
(Crapper McLachlan et al., 1991). In another in vivo study using APP2576 transgenic mice, an
animal model for AD, oral treatment with CQ a Cu/Zn chelator that stabilizes HIF-1 protein
induced marked inhibition of Aβ deposition (49% decrease) in the absence of any neurotoxicity
(Cherny et al., 2001). In a phase II clinical trial, CQ treated patients showed less cognitive
decline and a decrease in plasma Aβ levels relative to patients treated with placebo (Ritchie et
al., 2003).

In other neurological disorders such as Parkinson and Huntington disease, increased HIF1 levels induced neuroprotective events (Correia and Moreira 2010). DFO a hypoxia mimetic
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agent and 3,4-dihydroxybenzoate, a pharmacological inhibitor of PHDs, prevent neurotoxicity in
the MPTP-mouse model of Parkinson’s disease through stabilization of HIF-1 protein levels (Lee
et al., 2009). The CQ treatment of a transgenic Huntington disease mouse model improved the
behavioral and pathological phenotype, decreased accumulation of huntingtin protein and striatal
atrophy. It also normalized blood glucose and insulin levels and extended lifespan (Nguyen et
al., 2005).

Role of HIF-1 in cancer

The identification of the HIF-1 pathway for cellular response to hypoxia led to numerous
studies that provide evidence for its role in cancer. Strong support for this conclusion is provided
by the VHL mutation that leads to cancer of the kidney. This disease is due to a germline
mutation in the vhl gene that leads to constitutive activation of HIF-1. In addition, solid tumors
are known to have hypoxic regions within their core, which is the consequence of inadequate
vasculature and high metabolic demand. To survive under hypoxic conditions, tumor cells must
overcome the tight regulation of HIF-1 activity. The stabilization of HIF-1 protein leads to
transactivation of genes involved in angiogenesis and anaerobic metabolism (Maxwell 2005).
These are some of the characteristics which tumor cells acquire during malignant progression,
suggesting that HIF-1α is a potential regulator of cancer progression.
Immunohistochemical analyses demonstrate that HIF-1α is overexpressed in many human
cancers including breast, cervix, brain, ovary, oropharynx, and uterus. In addition, its
overexpression is correlated with the poor clinical outcomes in these patients (Semenza 2003). In
contrast, HIF-1α overexpression was also found to be associated with increased survival in the
patients with head and neck cancer and also non-small cell lung cancer. Not all of the more than
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70 genes regulated by HIF-1 favor cellular adaptation and survival. BCL2-interacting protein
(BNIP3) is HIF-1 target protein which is an inducer of apoptosis. In some cell types, HIF-1
activation was shown to play a pro-apoptotic role (Sowter et al., 2001; Bruick 2000)) and is also
a mediator of cell cycle arrest in hypoxia (Schipani et al., 2001; Goda et al., 2003)). Thus, the
contribution of HIF-1α activation to oncogenesis could also result from the environmental,
epigenetic and genetic parameters (Maxwell 2005). In addition, the function of HIF-1α may also
be dependent on the type of cancer as well as the stage of the cancer progression (Semenza
2003).
Pancreatic cancer cells, PCI-10, which were overexpressing exogenous HIF-1α showed a
significant increase in the frequency of xenograft growth post injection (Akakura et al., 2001).
This study revealed that transfection of HIF-1α into a series of pancreatic cancer cells that were
not expressing HIF1α at high levels, made these cells more resistant to apoptosis and also
resulted in increased tumorgenicity. Hypoxia-induced or exogenous overexpression of HIF-1α
directly increased in vitro invasion by the human colon adenocarcinoma cells, HCT116
(Krishnamachary et al., 2003). HIF-1α overexpression in tumor xenografts of HCT116 cells
resulted in increased growth and angiogenesis (Ravi et al., 2000).
In addition to overexpression of HIF-1α, the inhibition of this subunit has also revealed
the relevance of HIF-1 to cancer pathology. Overexpression of a dominant-negative form of
HIF-1α in PCI-43, pancreatic cancer cells, resulted in an increase in apoptotic cells and a
decrease in their ability to form tumors in SCID mice (Chen et al., 2003). Inhibition of HIF-2α
by siRNA was recently shown to significantly decrease the growth of neuroblastoma tumor
xenografts in athymic mice. HIF-2α was shown to mediate the chronic response of the cells to
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hypoxia, while HIF-1α was implicated in the acute hypoxia response (Holmquist-Mengelbier L
et al., 2006).
Recently, HIF-1α was shown to be overexpressed in preneoplastic hepatocytic lesions
from a very early stage of hepatocarcinogenesis in mice and humans. Interestingly, oxygen
tension within the lesions was not different compared to surrounding normal hepatic tissue,
indicating HIF-1α expression was hypoxia independent. In addition, this hypoxia-independent
expression of HIF-1α in hepatocarcinoma was shown to be regulated by the PI3K/AKT pathway
(Tanaka et al., 2006). In a separate study, the AKT pathway was also shown to be involved in
hypoxia-independent upregulation of HIF-1α. This factor was shown to contribute to
angiogenesis in human gastric cancer (Lee et al., 2007).

Role of HIF-1 in melanoma

Although, HIF-1 has been extensively studied in various cancers, information about its
role in melanoma biology is relatively limited. This area of research is critical, since the normal
human melanocyte resides at the base of the epidermis where there is a partial hypoxic
environment (Stewart et al., 1982). Evidence has been provided that this partial hypoxia
contributes to melanomagenesis. The hypoxic stress is thought to contribute to the Ras and AKTinduced transformation of normal human melanocytes (Michaylira and Nakagawa, 2006). In
another study an active AKT pathway in the presence of hypoxia was sufficient to transform
melanocytes. Interestingly, this effect was mediated via HIF-1α activation, and inhibition of HIF1α inhibited AKT-hypoxia induced transformation of melanocytes (Bedogni et al., 2005). In an
other study, Notch-1, an effector of AKT signaling, along with hypoxia was shown to promote
melanoma development (Bedogni et al., 2008).
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A majority of human melanomas have constitutively active MAPK/extracellular signalregulated kinase (ERK) due to BRAF or N-Ras mutations (Omholt et al., 2003; Daniotti et al.,
2004). Activation of this pathway is correlated with the upregulation of HIF-1α mRNA in human
melanoma (Kumar et al., 2007; Chun et al., 2003). A recent study investigated the involvement
of HIF-1 in uveal melanoma migration, invasion and adhesion (Victor et al., 2006). We recently
reported HIF-1α is over expressed in melanoma cells under non-hypoxic conditions and its
enhanced expression contributes to some of their malignant properties. In addition, the
experiments described in this report have demonstrated that the ERK1/2 MAPK pathway is not
likely involved in the upregulation of HIF-1α in melanoma cells (Mills et al., 2009).
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Microphthalmia-associated transcription factor (MITF)
Microphthalmia-associated transcription factor (MITF) is a master regulator of
melanocyte development, survival and function through activation of genes that play a role in
differentiation and cell-cycle progression. Melanocytes are pigment producing cells derived from
the neural crest. During development neural crest cells emerge from the neural tube and migrate
to the ectoderm where melanoblasts fully differentiated to melanocytes. These melanoblasts also
function as melanocyte stem cells and reside in a niche within the bulge region of hair follicles.
Melanocytes are found to be present in hair follicles, the basal layer of the epidermis, the inner
ear, the eye choroid, the Harderian glands and the heart. The major function of melanocyte in
skin and hair is the production of the melanin pigment to protect skin against harmful solar UV
radiation. Researchers have intensely studied the mechanism of melanocyte development,
melanin production, transport of this pigment through the melanosome and finally transfer of the
melanosome and release of melanin to the surrounding keratinocytes (Goding 2000; Cheli et al.,
2009).

The molecular mechanism responsible for the melanocyte development was dissected in
1993-94. The analysis of the promoter region of tyrosinase (TYR), tyrosinase related protein 1
(Tyrp-1) and others that play a role in melanin synthesis share a common 11bp element AGTCATGTG, termed the M box, which is required for their expression (Lowings et al., 1992). The
core CATGTG (E-box) motif within M box was known to bind basic-helix-loop-helix (bHLH)
and bHLH-Leucine Zipper (bHLH-LZ) families of transcription factors. It was found that Mitf, a
gene that encodes a bHLH-LZ transcription factor, was responsible for regulating melanin
synthetic genes as well, as many other genes involved in melanocyte development and
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differentiation (Hodgkinson et al., 1993; Hughes et al., 1993). Also in melanocytes, MITF acts
as a mediator for the α-melanin stimulating hormone (α-MSH) induced differentiation effects on
melanin production.

MITF belongs to the MiT family that consists of other related factors, including
transcription factor EB (TFEB), TFE3, and TFEC that bind E-box sequences. These transcription
factors share a highly conserved transactivation domain and bHLH-LZ domain that mediates
DNA binding and dimerization respectively. MITF can heterodimerize with TFEB, TFE3 and
TFEC under in vitro conditions but cannot heterodimerize with other bHLH-LZ transcription
factors such as myc, max or USF. Unlike cell type specific MITF, other members of this family
are thought to be ubiquitously expressed and do not appear to play a role in melanocytic
development. Although, TFE3 was found to be overexpressed in B16 melanoma, it fails to
coimmunoprecipitate along with MITF protein. This and other studies indicate that MITF is the
only MiT family member that functions as a homodimer and is essential for the normal
development of melanocytes (Goding 2000).

Characterization of the Mitf gene has led to the identification of at least nine different
MITF isoforms that differ in their transcriptional initiation sites: MITF-A, -B, -C, -D, -E, -H, -J, M and -MC. (Figure 1.7). The MITF variants differ in exon one while they have identical exons
from two to nine. Structurally, the functional domains like TAD and bHLH-LZ are encoded in
these common exons two to nine (Levy 2006). Whether, the unique N-teminal of these MITF
isoforms confers distinct properties on each protein, or whether they simply reflect the fact that
correct temporal or spatial expression of MITF could only be achieved using different promoters,
is not known. MITF-A is the largest and –M is the shortest isoform. Some of these isoforms are
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cell type specific such as MITF-M, which is specifically expressed in melanocytes and –MC,
which is expressed only in mast cells. In contrast -A is ubiquitously expressed. Among all of
these isoforms, MITF-M, has been the target of most experimental studies (Goding 2000).

Figure 1.7: MITF isoform differ in their transcriptional initiation sites. In humans, nine
different promoters have been described for MITF. These promoters give 50 specificity for
each isoform. However, all the different isoforms have in common exons 2 to exon 9, which
encode the functional domains of the transcription factors. These domains are the
transactivation domain (TAD) and the b-HLH-Zip. Some of the isoforms are expressed in
specific cell types, such as the isoform M, which is expressed specifically in melanocytes, and
the isoform MC, which is expressed selectively in mast cells (Levy et al., 2006).

Transcriptional and post-translational regulation of MITF

MITF-M is transcribed from an alternate promoter region located between exon one and
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two and is often referred to as M promoter. The transcription factors that are known to regulate
the M promoter have great significance in neural crest development and signaling. The
transcription factors that are included in this list are paired box gene 3 (PAX3), cAMPresponsive element binding protein (CREB), SRY (sex-determing region Y)-box 10 (SOX10),
lymphoid enhancer-binding factor 1 (LEF1), one cut domain 2 (ONECUT-2) and MITF itself
(Levy 2006). The well studied signaling mechanism that regulates MITF-M expression is the αMSH stimulated adenylyl cyclase pathway. α-MSH binds to the melanocortin 1 receptor
(MC1R), which activates adenylyl cyclase activity resulting in increased level of cAMP. This
increase in cAMP activates PKA, which among other substrates, phosphorylates CREB. This
transcription factor stimulates the MITF-M promoter by binding to a cAMP response element
(CRE) (Price et al., 1998). Although the adenylyl cyclase pathway is ubiquitous, the activation of
MITF-M promoter is melanocyte specific. The reason for this specificity is that CREB mediated
expression of MITF-M is dependent on SOX10 and, moreover, SOX10 mediated expression of
MITF-M is also CRE based. Thus, there is a certain level of co-operativity between these two
transcription factors restricted to only neural crest derived cells (Huber et al., 2003). The
wingless (WNT) signaling pathway is also important for the differentiation of melanocytes from
neural crest cells. Activation of this pathway leads to the stabilization of β-catenin, which in turn
interacts with LEF1 and is involved in activation of the MITF-M promoter (Dorsky et al., 2000;
Takeda et al., 2000; Widlund et al., 2002).

MITF protein can also be regulated at the post-translational level. MITF protein is
phosphorylated by MAPK, ribosomal S6 kinase (RSK), glycogen synthase-3β (GSKβ) and p38;
the change in phosphorylation can modulate its transcriptional activity during specific
environmental responses. Activation of c-kit in melanocytes results in phosphorylation of MITF
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at Ser73 by ERK2 and Ser409 by p90RSK. Although phosphorylation of MITF at Ser73 can
increase MITF activity by recruiting the transcriptional co-activator p300 (CBP),
phosphorylation at this site also subjects MITF to ubiquitination and degradation. The MITF
protein also gets sumolyated by protein inhibitor of activated STAT3 (PIAS3), and this seems to
affect its transcriptional activity in a target-gene-specific manner. MITF was also found to be a
substrate for proteolytic degradation at its C-terminus by caspase 3 (Levy, 2006).

PIAS3 and protein kinase C interacting protein 1 (PKCI) have been shown to be involved
in repressing MITF transcriptional activity by directly interacting with and inhibiting its DNA
binding activity. The phosphorylation patten of MITF is shown to affect PIAS3 interaction.
Phosphorylation at Ser73 increases the interaction between PIAS3 and MITF while
phosphorylation at Ser409 decreases this interaction (Levy 2006).

MITF target genes

Seventeen years after the role of MITF was first described in melanocyte biology, more
than 40 genes have been identified as targets of this key transcription factor. MITF is involved in
a complex cascade of gene regulation that plays a role in melanocyte growth, survival and
differentiation (Figure 1.7) (Cheli et al., 2009).

In the melanocyte differentiation program, MITF regulates genes that are involved in
melanin production, melanosome biogenesis, melanosome transport and signaling pathways.
Melanin synthesis is an enzymatic mechanism that converts tryrosine to a melanin pigment. The
first

two

steps

of

melanin

production

are

the

hydroxylation

of

tyrosine

to

dihydroxyphenylaalanine (DOPA) and oxidation of DOPA to DOPA quinine. Both of these steps
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involve tyrosinase (TYR) enzyme as a catalyst. Two other enzymes, tyrosinase-related proteins 1
(TYRP1) and dopachrome tautomerase (DCT), are also involved in melanin synthesis (Cheli et
al., 2009). MITF transactivates the TYR, TYRP1 and DCT promoters as demonstrated by
reporter gene assays and further directs binding to the promoter region of these genes within
whole cells (Bentley et al., 1994; Bertolotto et al., 1998; Yavuer et al., 1995; Cheli et al., 2009).

Melanin synthesis takes place in the melanosomes, which are lysosome-related
organelles. The biogenesis and transport of the melanosome are also key determinants of melanin
synthesis and skin pigmentation. In addition to TYR and DCT, other proteins in melanosomes
can also play an important role in melanogenesis. The Silver homologue (SILV) and Melan-a
(MLANA) are involved in the formation of the melanosomal matrix and melanosome
maturation. Loss of function by these proteins leads to pigmentary defects. Initially, MITF was
predicted to regulate SILV as its homologue, Pmel17, expression was undetectable in MITFmi
/MITFmi embryos. Confirmation was obtained through reporter gene assays and ChIP assays.
Therefore, MITF directly binds and transactivates the SILV and MALNA genes (Baxter and
pavan 2003; Du et al., 2003; Cheli et al., 2009). Other proteins that are involved in melanosome
biogenesis such as ocular albinism type 1 (GPR143) have also been reported as a direct target
gene of MITF. GPR143 is a G-protein coupled receptor protein that is located at the plasma
membrane and is involved in melanosome maturation and size (Cheli et al., 2009).

Rab27A a small GTP binding protein plays a role in melanosome transport along with
melanophilin and MyosinVa. Mutation in any one of these 3 genes leads to hypopigmentation as
found in Griscelli syndrome. By knockdown / overexpression studies and reporter gene assays it
was found that MITF is involved in transcription of Rab27A, indicating that MITF controls
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melanosome transport (Cheli et al., 2009). The human MC1R promoter contains an E-box and is
activated by MITF in gene reporter assays. MC1R is a G-protein coupled receptor that binds αMSH and plays a major role in skin pigmentation by activating MITF expression through the
adenylyl cyclase/cAMP/PKA/CREB pathway (Busca and Ballotti 2000).

Figure 1.8: MITF regulation and role in melanocyte differentiation, cell cycle progression
and survival. MITF is activated by various signaling pathways such as growth signaling
pathway involving ERK-MAPK activation, α-MSH mediated activation of adenyl cyclase
pathway and Wnt signaling pathway. MITF forms a homodimer and binds to E-box. MITF
transactivate various genes involved in cell cycle progression, differentiation and pigmentation,
motility and anti-apoptosis.
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In melanocyte development, MITF regulates genes that are involved in melanocyte
precursor growth and survival. During the embryonic development of mutant MITFmi-ew (eyeless
white) mice, melanoblasts were detected in the early stage but not in the late stages. These
mutant mice lacked melanocytes in the skin likely due to a defect in proliferation (Nakayama et
al., 1998) leading to growth arrest or cell senescence. In this context, MITF was shown to be the
target transcription factor TBX2, a member of the T-box family, which inhibits cell senescence
through downregulation of the p21 and p19 genes. MITF regulates TBX2 expression through the
E-box sequence located in its promoter region. TBX2 was the first MITF regulated gene
identified that is not directly involved in melanin synthesis. Other studies found that cyclindependent kinase (CDK2), a gene involved in cell cycle progression, was also regulated by
MITF. The promoter region of human CDK2 had a CATGTG motif (a same motif involved in
the regulation of SILV by MITF), located -1315 bp from the transcription start site. MITF was
found to regulate the expression of CDK2 by binding to its promoter region containing these
motifs (Cheli et al., 2009).

MITF was further linked to cell cycle progression by stimulating the transcription of
diaphanous-related formin (DIAPH1). Inhibiting the expression of MITF in melanoma was
found to upregulate p27 expression, a gene that is involved in inhibiting cell cycle progression
(Carreira et al., 2006). The upregulation of p27 was associated with the downgregulation of
diaphanous-related formin (DIAPH1), which controls the expression of p27 through
ubiquitination and degradation (Mammoto et al., 2004; Schulman et al., 2000). Analysis of the
DIAPH1 promoter showed three potential MITF binding sites. ChIP, electromobility shift assays
(EMSA) and reporter gene assays demonstrated that MITF binds and transactivates the DIAPH1
promoter. In addition this study also showed that silencing of MITF blocks melanoma cell cycle

31

progression in G0/G1. However, MITF may also directly regulate p21 and p16 that results in G1S arrest in melanocyte and melanoma. An E-box has been identified in the promoter of p21 but
whether a similar sequence is in p16 has not been determined. Silencing of MITF in a uveal
melanocyte cell line decreased p16 expression and increased cell proliferation while over
expression of MITF increased the expression of both p16 and p21 expression and blocked the
cell proliferation in a fibroblast cell line (Cheli et al., 2009).

The first evidence for the role of MITF in melanocyte survival comes from the microarray analysis of MITF dependent gene expression. Through this study BCL2, an anti-apoptotic
gene was identified as a potential target gene of MITF. Further analysis of the BCL2 promoter
revealed the presence of an E-box motif and ChIP, EMSA and reporter gene assays confirmed
BCL2 as the direct target of MITF. Furthermore, overexpression of BCL2 rescued the apoptotic
effect induced by dominant negative MITF (Mcgill et al., 2002). Thus, indicating that MITFstimulated BCL2 controls melanoma cell survival. In addition, BCL2 knockout mice are born
pigmented but later turn grey due to loss of melanocyte stem cells, thus indicating its role in
survival of melanocyte precursors (Mak et al., 2006; Veis et al., 1993). Recently, other antiapoptotic protein, BIRC7 (ML-IAP, LIVIN or KIAP) have been identified as direct targets of
MITF (Dynek et al., 2008).

Two independent reports showed that MITF can regulate met proto-oncogene (hepatocyte
growth factor receptor) (MET) expression. The MITF binding E-box motif was found in the
promoter of MET but only one of these studies confirmed that the regulation of MET promoter
activity by MITF was mediated by these motifs (Mcgill et al., 2006; Beuret et al., 2007).
However in both studies, MET activation was associated with the migration of melanoma cells
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and protected melanoma and melanocyte cells from apoptosis. MITF also regulates growth
signaling receptors such as KIT and NGFR through direct transactivation of their genes. KIT and
NGFR are tyrosinase kinase receptors involved in activating ERK/MAPK and PI3K signaling
pathways that play a role in protecting cells against apoptosis and favor cell survival (Cheli et al.,
2009).

Recently, MITF was found to play a role in protecting cells against the damage induced
during oxidative stress. The apurinic/apyrimidinic endonuclease1/redox factor-1 (APEX1) was
shown to be a direct target gene of MITF and its forced expression reversed ROS-induced
apoptosis in MITF silenced cells (Liu et al., 2009). In addition HIF-1α was recently found as a
direct target of MITF in melanoma cells. MITF stimulated HIF-1α expression was also shown to
protect these cells against apoptotic stimuli (Busca et al., 2005).

Physiological role of MITF

In humans, mutation in the Mitf locus leads to Waardenburg syndrome (WS) type IIA. It
is a dominantly inherited auditory-pigmentary syndrome mainly due to the absence of
melanocytes in the eye, inner ear, skin and hair. The most serious consequences of Mitf mutation
in affected individuals is hearing impairment that ranges from mild to severe. In the inner ear,
melanocytes reside in the stria vascularis of the chochlea where it maintains extracellular K+ in
the endolymphatic fluid. There are different types of WS; WS type I and type III are caused by
mutated PAX3, which is found to be expressed in neural crest cells and is a modulator of MITF.
PAX3 also affects lineages other than melanocytes. Thus, the WS type I and III patients, in
addition to melanocytic abnormalities, also exhibit musculoskeletal abnormalities. WS type IV is
caused by a mutation in SOX10, endothelin-1 and its receptor. It is characterized by melanocyte
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related deficiencies as seen in type I and also it exhibits Hirschsprung syndrome that involves
enlargement of the colon (Read and Newton 1997; Levy et al., 2006).

Studies on mutations of the Mitf gene in mice found alterations in phenotypes
characterized by deafness, bone hyperdensity, small eyes and a lack of pigmentation in eyes and
skin. Mutations in the Mitf gene that inhibit its function result in complete loss of pigmentation
due to an absence of melanocytes. However, the heterozygous mutants showed either no
pigmentation or a white spot on their belly. These white belly mice have a mutation within the
basic DNA binding domain of MITF while the HLH-Zip region responsible for dimerization is
unchanged. The ventral spotting in these dominant mutant mice is due to the defect in neural
crest migration of melanocyte precursors (Levy et al., 2006). According to hypomorphic allele
studies in mice, MITF is also necessary in adulthood and loss of function could lead to premature
gray hairs due to low maintenance of melanocyte stem cells (MSC) in the hair follicle bulge
region niche (Lerner et al., 1986; Nisthimura et al., 2005).

In addition to MITF’s role in melanocyte mediated pigmentation, it also seems to play a
role in development of melanocyte precursors from neural crest cells. The study conducted by
Hornyak et al. in Mitfmi/mi mutant mice revealed MITF is required for the survival and
development of melanoblasts during or immediately after the migration from the dorsal neural
tube. It also directly or indirectly affects the rate at which the number of melanoblasts migrate
from the neural tube. MITF is also related to MSC which are a self renewing population of
melanocytes that reside in the bulge region niche of the hair follicle. MSCs are involved in
maintenance of hair coloration and loss of MSC could lead to premature graying of the hair
(Hornyak et al., 2001). The Mitfvit mutant mice have premature loss of the MSC population

34

resulting in gray hair, a process normally associated with aging (Nisthimura et al., 2005).
Moreover, the anti-apoptotic gene BCL2 which is a direct target gene of MITF was shown to be
involved in maintenance of MSC in postnatal mice (Nisthimura et al., 2005; Steingrimsson et al.,
2005).

In addition to MITFs role in melanocyte function, it is also found to be expressed in mast
cells and osteoclasts. Mast cells play a central role in generating innate immunity against
bacterial and parasitic infections. They also serve as a mediator of allergic hypersensitivity
reactions in various pathological conditions. The Mitfmi/mi mutant mice which showed defects in
mast cells were more susceptible to parasitic infection relative wild type mice. The various
proteins such as proteases, protease inhibitors, adhesion molecules, metabolic enzymes and
growth factor receptors that play roles in mast cell maturation and function have been identified
as MITF target genes. Analogous to mast cells, osteoclasts arise from hematopoietic stem cells
and are found to play a role in bone remodeling. Osteoclast dysfunctionality in humans and mice
leads to osteoporosis making bones more brittle. The semi-dominant Mitf mutant mice have
shown to develop osteoporosis and reintroduction of intact MITF have rescued some of these
effects. MITF is shown to target genes such as TRAP, cathepsin K, OSCAR, E-cadherin, OSTM1
and Clcn7 that are involved in osteoclast function (Cheli et al., 2009).

Role of MITF in melanoma

In addition to MITFs role in melanocyte function, survival and differentiation, it was
found to be amplified as an oncogene in a fraction of melanomas. Analysis of primary melanoma
tissue microarrays found MITF to be amplified in 10-20% of cases of advanced melanoma.
Moreover, amplification of MITF in melanoma was associated with a decrease in the five year
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survival rate relative to patients who did not have this gene amplification. In addition, the ectopic
expression of MITF in conjuction with B-RAF (V600E), p53 and CDK4 mutations transformed
immortalized primary human melanocytes, thus defining MITFs role as an oncogene in
melanoma development (Garraway et al., 2005; Levy et al., 2006).

MITF expression is variable among melanoma specimens. In some cases, it was shown to
be more highly expressed in early stage relative to late stage melanoma (Salti et al., 2000; Selzer
et al., 2002). MITF levels seem to correlate with the levels of transient receptor potential cation
channel M1 (TRPM1) which is a target gene of MITF. TRPM1 expression is found to be highly
expressed in benign nevi, dysplastic nevi and melanomas in early stage and low in invasive
melanoma and virtually absent in metastatic melanomas. MITF expression was found to follow
the same trend as TRPM1 expression in melanomas. Recently, MITF has been identified as a
marker in the proliferative signature of melanoma cells that were less motile than invasive cells.
Melanoma cells with a proliferative signature initiated tumor growth in 14 days post injection
relative to melanoma cells have an invasive signature, which took 59 days (Hoek et al., 2008). In
another study MITF was identified as an oncogene in melanoma specimens representing the
transition point for tumor progression and metastasis (Riker et al., 2008). Because of these
opposing findings, there is controversy regarding the role of MITF in melanoma development
and progression.

The growth and survival function of MITF in melanoma remains a matter of debate. It
has been demonstrated that overexpression of MITF in melanoma cell lines reduced their
xenograft tumor growth (Selzer et al., 2002) by activating cell cycle inhibitors INK4 (Loercher et
al., 2005) and p21CIP1 (Carreira et al., 2005). However, MITF has been shown to up-regulate, the
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anti-apoptotic gene BCL2 (McGill et al., 2002) and to promote melanoma cell growth by
stimulating CDK2 expression (Du et al., 2004). Targeting MITF through direct injection of
siRNA into tumors drastically reduced the growth of B16 melanomas in syngenic mice by
inducing apoptosis (Nakai et al., 2007). This latter study, suggests that in some melanomas
MITF is a pro-survival factor.

Over the years, MITF has been described as a diagnostic marker in clinical determination
of melanoma. Its high sensitivity and specificity as an immunohistochemical marker is
considered superior to other melanoma markers such as S-100 and HMB-45 (King et al., 1999)).
One of the immunohistochemical markers which is currently used in clinical diagnosis of
melanoma is the MITF-specific antibody D5. However, MITF serves more as a melanocytelineage specific marker and cannot distinguish between benign vs malignant melanoma lesions
(Levy et al., 2006).
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Experimental objective
The major objective of this study was to determine if HIF-1α, a master regulator of
oxygen homeostasis, also plays a role in melanoma cancer progression. In this study we have
found that hypoxia-independent expression of HIF-1α protein in melanoma cells contributes to
its progression. In addition, we have found that MITF, a melanocyte specific protein (Levy et al.,
2006), is a novel direct target gene of HIF-1α in melanoma cells and high expression of MITF
plays a role in melanoma cell survival.
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Abstract
Hypoxia inducible factor-1 alpha (HIF-1α) protein is rapidly degraded under normoxic
conditions. When oxygen tensions fall HIF-1α protein stabilizes and transactivates genes
involved in adaptation to hypoxic conditions. We have examined the normoxic expression of
HIF-1α RNA and protein in normal human melanocytes and a series of human melanoma cell
lines isolated from radial growth phase (RGP), vertical growth phase (VGP) and metastatic
(MM) melanomas. HIF-1α mRNA and protein was increased in RGP vs melanocytes, VGP vs
RGP and MM vs VGP melanoma cell lines. We also detected expression of a HIF-1α mRNA
splice variant that lacks part of the oxygen-dependent regulation domain in WM1366 and WM9
melanoma cells. Over-expression of HIF-1α and its splice variant in the RGP cell line SbCl2
resulted in a small increase in soft agar colony formation and a large increase in matrigel
invasion relative to control transfected cells. Knockdown of HIF-1α expression by siRNA in the
MM WM9 melanoma cell line resulted in a large decrease in both soft agar colony formation
and matrigel invasion relative to cells treated with non-specific siRNA. There is a high level of
ERK1/2 phosphorylation in WM9 cells, indicating an activated Ras-Raf-MEK-ERK1/2 MAPK
pathway. Treatment of WM9 cells with 30 μM U0126 MEK inhibitor, decreased ERK1/2
phosphorylation and resulted in a decrease in HIF-1α expression. However, a 24 h treatment
with 10 μM U0126 totally eliminated Erk1/2 phosphorylation, but did not change HIF-1alpha
levels. Furthermore, siRNA knockdown of MEK siRNA did not change HIF-1alpha levels. We
speculate that metabolic products of U0126 decrease HIF-1α expression through "off target"
effects. Overall our data suggest that increased HIF-1α expression under normoxic conditions
contributes to some of the malignant phenotypes exhibited by human melanoma cells. The
expanded role of HIF-1α in melanoma biology increases its importance as a therapeutic target.
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Introduction

The incidence of melanoma is increasing more rapidly than any other tumor site.
Melanoma accounts for 4% of all skin cancers, but for 79% of all skin cancer related deaths in
the United States (Melanoma Research Foundation). Metastatic melanoma is highly resistant to
both chemo- and radiotherapy (Soengas and Lowe, 2003). Cutaneous melanoma arises from,
melanocytes, presumably due to early childhood exposure of the skin to UV radiation. A
predisposing factor for melanoma may be the melanocortin receptor. It has been found that
individuals having a mutation that affects the function of the melanocortin receptor have an
increased risk of developing cutaneous melanoma (Sturm 2002).
Hypoxia-inducible factor-1 (HIF-1) is a master regulator of O 2 homeostasis in cells. It
consists of a heterodimeric transcriptional complex of two proteins, HIF-1β and HIF-1α. HIF1β is constitutively expressed whereas HIF-1α protein is stabilized only under hypoxic
conditions, despite its continuous synthesis under normoxic conditions (Semenza 2003). When
O 2 tension is normal, HIF-1α is hydroxylated at specific proline residues by the enzyme prolyl
hydroxylase-domain (PHD). This hydroxylation is required for the von Hippel Lindau (VHL)
tumor suppressor protein to bind to HIF-1α leading to subsequent ubiquitination and
proteasome-targeted degradation (Maxwell et al., 1999). VHL binding is also enhanced by
acetylation of lys532 catalyzed by the acetyltransferase, ADP-ribosylation factor domain protein
1 (ARD1) (Jeong et al., 2002). Under hypoxic conditions, proline hydroxylation decreases
thereby stabilizing HIF-1α, which in turn moves to the nucleus and transactivates various genes
containing hypoxia response elements (Semenza 2002).
HIF-1α controls the expression of over 60 genes involved in many aspects of
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oncogenesis, including tumorigenesis (Kondo et al., 2005; Zhang et al., 2004) anti-apoptosis
(Zhang et al., 2004; Greijer and Wall 2004), and genetic instability (Koshiji et al., 2005). HIFα
has also been implicated in the malignant progression of several cancers including mammary
gland, prostate, brain, and lung (Goda et al., 2003). HIF-1α is the regulatory subunit of HIF-1.
It is regulated at the protein level by both oxygen- dependent and independent pathways
(semenza 2002). HIF-1α is highly expressed in early stage of mouse hepatocarcinogenesis
independent of hypoxia (Tanaka et al., 2006). The hypoxia independent increase in HIF-1α is
thought to be activated by growth signaling pathways. A majority of human melanomas have
constitutively active MAPK/extracellular signal-regulated kinase (ERK) due to BRAF or NRas mutations (Omholt et al., 2003; Daniotti et al., 2004). Activation of this pathway is
correlated with the upregulation of HIF-1α mRNA in human melanoma (Kumar et al., 2007;
Chun et al., 2003). However the biological significance of upregulated HIF-1α under normoxic
conditions for initiation and progression of melanoma has not been elucidated.
In this study, we examined the normoxic expression and biological functions of HIF-1α
in human melanoma. We found that both full length and a splice variant, HIF-1α785, are
expressed in human melanoma cell lines while essentially undetectable in normal human
melanocytes. Ectopic HIF-1α expression in a low expressing RGP cell line stimulated Matrigel
invasion, while knockdown of HIF-1α in a high expressing MM cell line inhibited both soft
agar colony formation and Matrigel invasion. Knockdown of MEK1/2 and loss of
phosphorylated ERK1/2 did not decrease HIF-1α expression. U0126 MEK inhibitor at 10 μM
eliminated ERK1/2 phosphorylation, but did not decrease HIF-1α expression.
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Results

Expression of HIF-1α in human melanoma cells
In addition to the well known pathway of HIF-1alpha protein stabilization under hpoxic
conditions, it has been established that many oncoproteins and growth factor signaling
pathways up-regulate HIF-1α expression under normoxic conditions (Stiehl et al., 2002;
Vogelstein and Kinzler 2004). However, there are few investigations into the normoxic
expression of HIF-1α in human melanoma and its role in the malignant progression of this
disease. Here, we show that in human melanoma cells, the oxygen-labile HIF-1α protein as
well as its mRNA is expressed endogenously under normoxic conditions. Figure 2.1A shows
that HIF-1α protein is highly expressed in WM9 cells relative to normal human melanocyte
(HEMn-LP), but radial growth phase (SbCl2), and vertical growth phase (WM1366) also
express a higher amount of HIF-1α protein relative to human melanocytes. Similar results are
seen in second set of RGP, VGP and MM melanoma cell lines (Figure 2.1B). HIF-1α was
detected as 120 kD protein in nuclear extracts while no protein was detected in cytoplasmic
extracts (data not shown).
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Figure 2.1 Expression of HIF-1α protein in human melanocytes and melanoma cells.
Nuclear extracts (30 μg) from HEMn-LP (normal human melanocytes), SbCl2 (radial growth
phase melanoma), WM1366 (vertical growth phase melanoma) and WM9 (metastatic
melanoma) (A) and WM3211 (radial growth phase melanoma), WM3248 (vertical growth
phase melanoma), WM239 (metastatic melanoma) (B) cell lines were analyzed by western
blotting using a monoclonal anti-HIF-1α antibody (1 μg/ml). LaminB1 was used as a loading
control. This blot is representative of at least 3 different experiments, all of which gave similar
results.

Hypoxic stabilization of HIF-1α occurs at the protein level (Semenza 2003). Since HIF1α protein was increased in human melanoma cells under normoxic conditions, we determined
whether this increase might be due to increased HIF-1α mRNA levels. Initially we used semiquantitative RT-PCR to assess expression of HIF-1α full length (FL) and a splice variant HIF1α785 that is missing the acetylation site lys532 due to lack of exon 11 (Figure 2.2A). This
splice variant encodes HIF-1α protein that has been reported to be stable under normoxic
conditions (Chun et al., 2003; Lin et al., 2004). Primers were designed so that full length HIF1α would exclude HIF-1α785 by targeting exon 11, which is absent in HIF-1α785. Primers for
HIF-1α785 excluded HIF-1α by targeting the exon 10:12 boundary only present in HIF-1α785.
Figure 2.2B shows that human melanoma cell lines express both full-length and the 785 splice
variant HIF-1α mRNA at a level that appeared to be higher than normal human melanocytes.
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Figure 2.2 Expression of HIF-1αFL & HIF-α785 mRNA in human melanoma cells. (A)
Schematic representation of the functional domains of both HIF-1α full length and HIF-1α785.
Both HIF-1αFL and 785 have various domains in common such as basic helix loop helix
(bHLH), Per/Arnt/Sim (PAS), Oxygen Dependent Degradation Domain (ODDD), N-terminal
transactivation domain N-TAD, inhibitory domain (ID), nuclear localization signal (NLS) and
C-terminal transactivation domain C-TAD. Upon loss of exon 11 in HIF-1α785, part of the
ODDD is deleted. This missing region contains the important lysine 532 residue which is
acetylated by ARD1 leading to increased stable interaction of HIF-1α with the von Hippel
Lindau tumor suppressor. This interaction directs HIF-1α to the ubiquitin-proteasome pathway
for degradation under normoxic conditions (Jeong et al., 2002). (B) Total RNA was extracted
from HEMn-LP, SbCl2, WM1366, and WM9. RNA was reverse transcribed using the
Advantage RT-for PCR kit®. Five μL of the resulting cDNA was used in the PCR reaction as
described in the Advantage cDNA kit® manual. Primers (see Methods for sequence) for HIF-1α
and HIF-1α785 were designed to specifically amplify each variant with no cross-amplification.
Primers for the housekeeping control gene GAPDH were included in the Advantage cDNA
kit®. Control primers amplifying a fragment of the control plasmid included in the Advantage
cDNA kit® were used to ensure optimal PCR conditions.

These findings were verified by qRT-PCR measurement of full-length and HIF-1α785
mRNA levels (Figure 2.3). All melanoma cell lines had increased expression of HIF-1α mRNA
relative to normal human melanocytes. In addition VGP and MM cell lines expressed more of
the 785 HIF-1α mRNA than full length HIF-1α mRNA. Overall the WM9 metastatic
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melanoma expressed the highest amount of 785 HIF-1α mRNA (~79× higher than normal
human melanocytes).

Figure 2.3 Quantitative analysis of HIF-1αFL & HIF-1α785 mRNA expression in human
melanoma cells. Total RNA was extracted from HEMn-LP, SbCl2, WM1366, and WM9 cells
at 72 h (A) after seeding. RNA was then converted to cDNA using the High Capacity cDNA
Archive Kit (ABI). Real-Time PCR analysis was performed using TaqMan probes directed at
HIF-1αFL or HIF-1α-785 as well as β-actin. The reactions were performed under conditions
specified in the ABI TaqMan Gene Quantification assay protocol. Data was corrected for
efficiency and loading using the Pfaffl method. Data is expressed as fold change, corrected for
β-actin, relative to HeMn-LP. (B) Real-time PCR analysis was performed using Taqman
probes directed at HIF-1αFL or HIF-1α785 as well as 18S using RNA extracted from HEMnLP, WM3211, WM3248, and WM239 cells. Data is representative of at least 2 separate
experiments.

HIFαFL and HIF-1α785 gain-of-function in radial growth phase SbCl2 cells
Gain of function studies means overexpressing HIF-1α in RGP cells and measuring its
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effect on their biological properties. The level of HIF-1α protein is low in the radial growth
phase SbCl2 cells relative to VGP or MET cell lines. We determined the effect of HIF-1αFL or
HIF-1α785 overexpression on SbCl2 anchorage-independent growth and Matrigel invasion.
HIF-1αFL and HIF-1α785 were cloned into the pLenti-V5-D-TOPO vector and transiently
overexpressed in SbCl2 cells (Figure 2.4A). HIF-1α785 overexpression resulted in a small, but
statistically significant increase in anchorage-independent growth, relative to mock or lacz
transfected cells (Figure 2.4C and 2.4D). In contrast overexpression of both HIF-1αFL and
HIF-α785 in SbCl2 resulted in a large and significant 3-fold increase in Matrigel invasion
relative to mock or Lacz transfected cells (Figure 2.4B).

Figure 2.4 Effect of HIF-1αFL and HIF-1α785 overexpression in radial growth phase
SbCl2 cells on anchorage-independent growth and invasion. SbCl2 cells were transiently
transfected at 80% confluence with either mock (no plasmid DNA), pLenti-V5-Lacz, pLentiV5-D-TOPO-HIF-1αFL or pLenti-V5-D-TOPO-HIF-1α785 using FuGene 6 transfection
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reagent. (A) After 48 h nuclear protein was extracted and over-expression was confirmed by
western blot using HRP-conjugated anti-V5 antibody and mouse monoclonal anti-HIF-1α
antibody (1 μg/ml). LaminB1 was used as loading control. (B) SbCl2 cells 24 h post
transfection with either mock (no plasmid DNA), Lacz, HIF-1αFL or HIF-1α785 were
subjected to Matrigel invasion assay as described in "Material and Methods". Results are
expressed as percent invasive cells corrected for invasion level of cells seeded in Matrigel (-)
chambers. (C&D). SbCl2 cells transfected either with reagents alone (mock), Lacz, HIF-1αFL
or HIF-1α785 were subjected to CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs,
Inc.) as described in "Material and Methods" for 4 (C) and 5 days (D). Results are expressed as
Relative Fluorescent Units. Data is expressed as the mean ± SEM of triplicate values. ANOVA
with TUKEY for multiple pairwise comparison was used to analyze the data and all P values≤
0.05 are relative to Mock and Lacz overexpressing cells. The entire experiment was repeated
two additional times with similar results.

HIF-1α loss-of-function in human metastatic melanoma WM9 cells
HIF-1α protein is highly expressed under normoxic conditions in the WM9 human
metastatic melanoma cell line. To determine whether HIF-1α could be contributing to the
malignant characteristics of these cells, we knocked down its expression and examine how this
affected anchorage independent growth and Matrigel invasion. WM9 cells were treated with
100 nM siRNA targeting HIF-1α (Dharmacon) which consistently decreased its expression by
~75-85% (Figure 2.5A). Colony formation after 5 days in soft agarose was inhibited by 70% in
HIF-1α-siRNA transfected WM9 cells in comparison to cells transfected with control siRNA
(Figure 2.5B). A photo (Figure 2.5C) of the colonies formed at this time point in control vs.
HIF-1α transfected cells verifies this decrease in soft agar colony formation. Matrigel invasion
was also significantly decreased in HIF-1α-siRNA transfected WM9 cells compared to control
siRNA transfected WM9 cells (Figure 2.5D). Measurement of cell viability in the Matrigel
chambers shows no difference between control vs. HIF-1α siRNA transfected cells (Figure
2.5E). These knock down studies suggest that increased non-hypoxic expression of HIF-1α
plays an important role in key malignant properties exhibited by these human melanoma cells.
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Figure 2.5 The effect of loss of HIF-1α expression in human metastatic melanoma WM9
cells on anchorage-independent growth and invasion. (A) WM9 cells were treated with
either 100 nM HIF-1α siRNA or 100 nM control non-targeting siRNA (Dharmacon, Inc.) using
the RNAifect® transfection reagent (Qiagen, Inc.). Knock down of HIF-1α was confirmed by
western blot at 72 h post transfection. (B) At 48 h post transfection Ctrl siRNA or HIF-1α
siRNA treated WM9 cells, were assayed for anchorage independent growth using the
CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.). Briefly, the cells were
seeded at 8.0 × 103 cells/well into a 0.4% agar layer poured over a 0.6% agar layer of a 96 well
plate. Wells lacking cells served as a blank control. On day 5 after seeding, agar layers were
solubilized, cells were lysed, and nucleic acid stained with CyQuant dye. Fluorescence intensity
in each well was determined by a plate reader set at 485/520 nm. Results are expressed as
Relative Fluorescent Units. (C) Photomicrograph of a representative field of colonies form in
the Cell Transformation Assay by control siRNA transfected cells (left) vs. HIF-1α siRNA
transfected cells. (D) Matrigel invasion assay. At 48 h post transfection, the Ctrl siRNA or HIF1α siRNA transfected WM9 cells were seeded into 6-well Matrigel (+) chambers, and as a
control, 6-well Matrigel (-) chambers (BD Biosciences) at 7.0 × 104 cells per well. The method
and counting of invading cells was done as described in "Experimental Procedures". Results are
expressed as % invasion of HIF-1α siRNA treated-WM9 cells relative to invasion by Control
siRNA treated-WM9 cells corrected for invasion by similarly treated cells seeded in Matrigel (-)
chambers. (E) Cell viability assay was done in WM9 cells transfected with control siRNA or
HIF-1α siRNA at 48, 72 and 96 h following transfection by the trypan blue exclusion method.
Data is expressed as the mean ± SEM of triplicate samples. The entire experiment was repeated
twice with similar results. Student paired t test was used to analyse the data and all P values ≤
0.01 or 0.05 are relative to control siRNA treated cells.

Regulation of HIF-1α expression in human melanoma by the ERK1/2 MAPK pathway
Hypoxia independent expression of HIF-1α is thought to be regulated by growth
signaling pathways (Stiehl et al., 2002; Vogelstein and Kinzler 2004) and the majority of
melanomas have constitutively active ERK1/2 MAPK pathway due to BRAF or N-Ras
mutations (Omholt et al., 2003; Daniotti et al., 2004). Therefore, we determined whether HIF1α expression in human metastatic melanoma WM9 cells was dependent on activation of
ERK1/2 MAPK signaling. These cells have an active ERK1/2 MAPK pathway as evidenced by
the high phosphorylation of ERK (Figure 2.6A). Treatment of WM9 cells with 30 μM U0126,
a selective U0126 MEK inhibitor, decreased ERK1/2 phosphorylation and led to a timedependent decrease in HIF-1α protein expression (Figure 2.6A). Although 30 μM U0126 has
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been used in published studies to selectively inhibit MEK (Kumar et al., 2007; Tisciuoglio et
al., 2004), the original paper describing this inhibitor (Favata et al., 2004) used much lower
concentrations to achieve high selectivity. Therefore we repeated this experiment using 10 μM
U0126 (Figure 2.6B). At 24 h of treatment, 10 μM U0126 completely suppressed the
phosphorylation of ERK1/2, yet there was minimal change in the level of HIF-1α relative to
control cells. With further time of inhibitor treatment, phosphorylation of ERK was not totally
suppressed, but HIF-1α levels decreased. We also used siRNA specifically targeting MEK1
and 2 in WM9 cells to inhibit ERK1/2 phosphorylation. Treatment of WM9 cells with siRNA
targeting MEK1 and 2 consistently decreased its expression by greater than 90% and also
decreased ERK1/2 phosphorylation. However, knockdown of MEK1 and 2 did not decrease the
normoxic expression of HIF-1α protein in human metastatic melanoma WM9 cells (Figure
2.6C).
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Figure 2.6 Effect of ERK1/2 MAPK inhibition on HIF-1α expression in human melanoma
cells. WM9 cells were treated with either 30 (A) or 10 (B) μmol/L U0126 a MEK1/2-specific
inhibitor or vehicle (DMSO). Inhibition of ERK phosphorylation and HIF-1α expression was
determined by western blotting at 24, 48 and 72 h after treatment using both total ERK,
phospho-specific ERK and HIF-1α antibodies respectively. C. WM9 cells were also treated
with either 100 nM MEK1&2 siRNA or 100 nM control non-targeting siRNA (Dharmacon,
Inc.) using the RNAifect® transfection reagent (Qiagen, Inc.). Knock down of MEK1&2 was
confirmed by western blot at 72 h post transfection. Inhibition of ERK phosphorylation and
HIF-1α expression was examined by western blot at the same time point in nuclear extracts by
using both total ERK, phospho-specific ERK, and HIF-1α antibodies. The entire experiment
was repeated two additional times with similar results.
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Discussion

Melanocytes - the cells responsible for producing the skin-coloring pigment, melanin,
are the point of origin for melanoma. Melanoma, if diagnosed and treated early, has a high cure
rate (Balch et al., 2001). If the melanoma progresses, it can metastasize regionally to lymph
nodes, and then to distant organs such as the lungs, and the brain (Houghton and Polsky 2002).
Metastatic melanoma is very difficult to treat and has a high mortality rate. Several studies
have confirmed that HIF-1α is a survival factor, as well as a key regulator of metastasis in
various cancers (Harris 2002; Liao et al., 2007).
HIF-1α regulates the adaptive responses to O 2 tensions at cellular levels. It controls the
expression of many genes involved in different aspects of tumor biology, including
angiogenesis, cell survival, invasion (Semenza 2003), tumor growth (Kondo et al., 2005;
Zhang et al., 2004), anti-apoptosis (Zhang et al., 2004; Greijer and Wall 2004), and genetic
instability (Koshiji et al., 2005). HIF-1α is rapidly degraded under normoxic condition and is
stablilized under hypoxic condition (Semenza 2003). We found that HIF-1α protein and RNA
is expressed under normoxic conditions in several human melanoma cell lines and that the
levels of HIF-1α expression correlates with the stage of cancer from which the melanoma cell
line was established. In contrast, HIF-1α protein was undetectable in normal human
melanocytes. Normoxic expression of HIF-1α has been found in a number of cancer cell types
(Tanaka et al., 2006; Kumar et al., 2007; Lee et al., 2007). Activation of the ERK1/2 MAPK
(Kumar et al., 2007) and phosphotidylinositol 3-kinase (PI3K) (Stiehl et al., 2002) pathways
has been implicated in stimulating normoxic expression of HIF-1α.
The epidermis of the skin is a partial hypoxic environment (Stewart et al., 1982).

53

Evidence has been provided that this partial hypoxia contributes to melanomagenesis (Bedogni
et al., 2005; Bedogni et al., 2008). Therefore, one possibility is that the increase in HIF-1α that
we observed in melanoma cells is due to the hypoxic adoptive response maintained by the cells
in culture. However, hypoxia stabilizes the HIF-1α protein and does not increase the level of
HIF-1α mRNA. We found that the increased HIF-1α protein in the melanoma cells was
correlated with an increase in HIF-1α mRNA. Also, the normal human melanocytes used in our
study came from the partial hypoxic environment of the skin and yet in culture, they do not
express detectable levels of HIF-1α protein. Therefore, we think it more likely that the
increased HIF-1α mRNA and protein is due to an inappropriately activated signaling pathway.
We also found that an mRNA splice variant, HIF-1α785, was expressed at higher levels
than full length HIF-1α mRNA in the VGP and metastatic human melanoma cell lines. HIF1α785 is missing the acetylation site lys532 due to lack of exon 11 and is thought to be more
stable under normoxic conditions in comparison to full length HIF-1α (Chun et al., 2003; Lin
et al., 2004). In several non-melanoma cell lines it was found that phorbol ester stimulated the
expression of HIF-1α785 mRNA under normoxic conditions via a redox-dependent ERK1/2
MAPK pathway (Kumar et al., 2007). How this alternatively spliced isoform of HIF-1α mRNA
is increased in melanoma is currently under investigation.
We examined the biological consequences of HIF-1α FL and 785 splice variant gain of
function and HIF-α FL loss of function in selected human melanoma cells. The SbCl2 radial
growth phase melanoma cells have low levels of HIF-1α protein expression and a limited
capacity to form colonies in soft agar and to invade through Matrigel. This cell line was chosen
to determine the biological effects of HIF-1α overexpression. Transient ectopic expression of
FL HIF-1α did not result in a statistically significant increase in SbCl2 colony formation in soft
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agar. However, transient overexpression of HIF-1α785 resulted in a small, but statistically
significant increase in soft agar colony formation. The effect on anchorage-independent growth
may be limited by the transient nature of the overexpression of HIF-1. Overexpression of either
HIF-1αFL or 785 led to a large and statistically significant increase in the ability of SbCl2 cells
to invade Matrigel. There have been a few reports on the effect of HIF-1α overexpression on
the in vitro biologic properties of cancer cells. Hypoxia-induced or exogenous overexpression
of HIF-1α increased in vitro invasion by human colon adenocarcinoma cells (Chun et al.,
2003), while stable normoxic overexpression of HIF-1α promoted anchorage-independent
growth in melanocytes having an activated AKT signaling pathway (Bedogni et al., 2008).
SbCl2 cells overexpressing HIF-1α785 showed a somewhat greater increase in soft agar colony
formation as well as invasion ability compared to full length HIF-1α. Whether this difference is
due to a longer half-life for the splice variant protein relative to the full length protein is
currently under investigation.
HIF-1α loss of function experiments were carried out in the WM9 metastatic melanoma
cell line. This cell line was chosen due to its high level of normoxic expression of HIF-1α. The
WM9 is an aggressive metastatic melanoma cell line that has a high level of anchorageindependent growth and Matrigel invasion ability. We found a significant decrease in both
anchorage-independent growth and Matrigel invasion upon silencing of normoxic expression
of HIF-1α by siRNA treatment. These decreases were not due to a loss of cell viability as has
been reported for knockdown of HIF-1α under hypoxic conditions (Kumar et al., 2007). This
decrease in invasion might be due to decreased expression of HIF-1α regulated genes involved
in invasion such as matrix metalloproteinase 2 (MMP2), urokinase plasminogen activator
receptor (uPAR), and cathepsin D (Krishnamachary et al., 2003; Luo et al., 2006). Loss of
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anchorage-independent growth in HIF-1α silenced cells may be due to ERK/MAPK, PI3K/Akt
and HIF-1 pathway interactions. The PI3K/Akt pathway is one of the most critical pathways
involved in anchorage-independent growth (Wang 2004).
Hypoxia independent expression of HIF-1α is thought to be regulated by growth
signaling pathways (Semenza 2002). The majority of melanomas have constitutively active
ERK1/2 MAPK pathway due to BRAF or N-Ras mutations (Omholt et al., 2003; Daniotti et
al., 2004). In particular, human metastatic melanoma WM9 cells have a constitutively active
ERK1/2 MAPK pathway most likely due to the V600E BRAF mutation found in these cells.
Treatment of these cells with 30 μM of the selective MEK inhibitor, U0126, decreased ERK1/2
phosphorylation and also resulted in a time dependent decrease in HIF-1α protein expression.
This 30 μM concentration chosen for our initial studies was based on two other
published papers that used this amount of U0126 to demonstrate the involvement of the
ERK1/2 MAPK pathway in the regulation of HIF-1α (Kumar et al., 2007; Tisciuoglio et al.,
2004). In the original report describing U0126, it was stated that the Ki for intracellular
inhibition of ERK phosphorylation in COS-7 cells was 0.1 μM (Favata et al., 1998). Thus the
concentration used in our study and others (Kumar et al., 2007; Tisciuoglio et al., 2004) is 300
times higher than the Ki. Therefore we repeated the MEK inhibition studies using 10 μM
U0126. In contrast to 30 μM U0126, the lower concentration completely eliminated ERK1/2
phosphorylation after a 24 h incubation with WM9 human metastatic melanoma cells. Despite
this inhibition of ERK1/2 phosphorylation, there was no change in the expression of HIF-1α
protein. At the later time point of 48 and 72 h of inhibitor treatment the phosphorylation of
ERK1/2 was not completely suppressed and the level of HIF-1α protein was decreased. We
also inactivated ERK1/2 signaling by knocking down the expression of MEK. We needed to
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use siRNA against both MEK1 and MEK2 in order to obtain a > 90% decrease in expression of
these enzymes. Although this knockdown inhibited ERK phosphorylation, there was no
decrease in HIF-1α protein expression at any time point assayed (up to 6 days). In the course of
analyzing these data, we were informed by Promega, the manufacturer of U0126, that the
compound is unstable in tissue culture media and produces metabolites that have poor MEK
inhibitory activity. Considering the sum of our data, we hypothesize that the metabolites of
U0126 are responsible for the decrease in HIF-1α protein levels. This would explain the lack of
change in HIF-1α protein in cells treated for 24 h with 10 μM U0126 despite complete
inhibition of ERK1/2 phosphorylation and the fact that siRNA knockdown of MEK resulting in
decrease ERK1/2 phosphorylation also did not result in a decrease in HIF-1α protein levels.

TABLE 1: Genotyping data of melanoma cell lines

Mutation

NRAS

WT/WT

V600E
BRAF

V600D
BRAF

Cell lines
Sbcl2

++

WM3211
WM1366

++
++

WM3248

++

WM9

++

WM239

++

The N-RAS or BRAF mutational status of melanoma cell lines RGP (Sbcl2, WM3211), VGP
(WM1366, WM3248), MM (WM9, WM239).

Analysis of BRAF and NRAS mutations in our human melanoma cell lines (Table 2.1)
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shows that WM3211 cells do not have the common activating mutations in these genes, yet
these cells express increased amounts of HIF-1α protein and mRNA under normoxic
conditions. Overall our data suggest normoxic expression of HIF-1α is not regulated by the
ERK1/2 MAPK pathway, at least in the WM9 human metastatic melanoma cell line. The
hypoxia independent expression in melanoma cells, like other cancers, might be regulated by
phosphotidylinositol 3-kinase (PI3K) (Tanaka et al., 2006; Stiehl et al., 2002), NFkB (Jung et
al., 2003) or JAK/STAT (Niu et al., 2008) pathways.
In conclusion, HIF-1α is overexpressed, in melanoma cell lines under normoxic conditions
in a manner that correlates with the aggressiveness of the tumor from which the cell line was
established. We also show that the novel splice variant HIF-1α785, which is missing part of the
oxygen regulation domain is overexpressed in these melanoma cell lines. Manipulation of HIF1α expression in several of our melanoma cell lines suggests that this transcription factors
regulates, in part, anchorage-independent growth and Matrigel invasion. Our results suggest
that development of new therapeutic agents that inhibit HIF-1α function may be of use in the
treatment of human melanoma regardless of the hypoxic condition of the tumor.
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Materials and methods

Cell lines and cell culture conditions
SbCl2, WM3211 (RGP), WM1366, WM3248 (VGP), and WM9, WM239 (Metastatic
melanoma) cells were a generous gift from Meenhard Herlyn's lab at the Wistar Institute
(University of Pennsylvania). All cells were grown in a humidified incubator with 5% CO 2 and
95% air at 37°C. The SbCl2 cells were cultured in MCDB153 media (Invitrogen, Carlesbad
CA), supplemented with 2% fetal bovine serum, 5 μg/ml insulin (Sigma Chemical, St. Louis,
MO), 1.68 mM CaCl 2 , 100 units/mL penicillin streptomycin solution (Invitrogen Corp.,
Carlsbad CA). WM3211 cells were cultured similar to Sbcl2 media except for 5% fetal bovine
serum and no CaCl2. WM1366, WM3248, WM9 and WM239 cells were cultured in RPMI
medium (Invitrogen Corp., Carlsbad CA) supplemented with 10% fetal bovine serum and 100
units/mL penicillin streptomycin solution. Normal human melanocytes (HEMn-LP) were
derived from human foreskin (Cascade Biologics, Portland, OR) and maintained in Medium
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254 supplemented with 50 mL HMGS (Cascade Biologics, Portland, OR) and 1 mL PSA
solution (Cascade). Maintaining all cell lines in RPMI media for 48 h did not change their level
of HIF-1α expression levels

Western Blot analysis
Nuclear extracts from each cell line were isolated using the NePER kit® (Pierce,
Rockford, IL) according to the manufacturers protocol. Protein concentration was determined
using the BCA protein assay reagents from Pierce as per the manufacturer's instructions.
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes using the
BioRAD MiniProtean3® system. Equal loading was also determined by Ponceau staining of the
nitrocellulose membranes. Blots were blocked using ChemiBlocker reagent (Chemicon,
Temecula, CA) for 1 hr at room temperature and probed overnight at 4°C with anti-HIF-1α
mouse monoclonal antibody at 1 μg/mL (R&D Systems, Minneapolis, MN), 1:1000 phosphop44/42 MAPK (Cell Signaling Tech Inc, Danvers, MA), p44/42 MAPK (Cell signaling Tech
Inc, Danvers, MA), total MEK1/2 (Cell Signaling Tech Inc, Danvers, MA), 1:2000 V5-HRP
(Invitrogen, Carlsbad, CA), 1 μg/mL Lamin B1 or Lamin A (Abcam, Cambridge, MA).
Monoclonal mouse secondary IgG antibody (GE Healthcare, Piscataway, NJ) or rabbit
secondary IgG antibody (Cell signaling) conjugated with HRP was applied after two 1× TBS +
0.05% Tween (TBS-T) washes. Blots were incubated with secondary antibody at 1:3000 for 1
h at room temperature and subsequently washed 2× with 1× TBS-T. A final 5 min wash with
TBS (no Tween) was performed just prior to incubating the blot with ECL reagent (GE
Healthcare, Piscataway, NJ). Blots were then autoradiographed and the density of
immunoreactive bands determined by a BioRad imaging system after correction by an internal
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protein standard such nuclear lamin.

RNA isolation and RT- PCR
Total RNA was extracted using Tri-Reagent (Sigma Chemical Co., St. Louis, MO). The
purified RNA samples were dissolved in RNase-free water and quantified by Nanodrop
spectrophotometer (NanoDrop Technology, Inc., Wimington, DE). Each RNA sample had an
A260/A280 ratio of 1.8 or above. The quality of RNA was determined on the Agilent 2100
Bioanalyzer, using the RNA 6000 Nano Assay kit (Agilent Tehcnologies, Wilmington, DE)
and reverse transcribed using the RT-for-PCR kit (Clontech, Palo Alto, CA) as per
manufacturer's instructions. Primers were designed to either amplify only HIF-1α or HIF1α785 exclusively. HIF-1α primers excluded HIF-1α785 by targeting exon 11, which is absent
in HIF-1α785. HIF-1α785 primers were designed to exclude HIF-1α by targeting the exon
10:12 boundary only present in HIF-1α785. Sequence of the HIF-1α forward primers were: 5'AAAGTTCACCTGAGCCTAAT-3', and reverse 5'-TAAGAAAAAGCTCAGTTAAC-3'. The
sequence of HIF-1α785 forward primers were 5'-AAAGTTCACCTGAGGACAC-3', and
reverse 5'-TAAGAAAAAGCTCAGTTAAC-3'. Primers for the housekeeping gene control
GAPDH were included in the Advantage cDNA kit®. Control primers amplifying a fragment of
the control plasmid included in the Advantage cDNA kit® were used to ensure optimal PCR
conditions. PCR was performed using thermocycler (Biometra Tgradient, Goettingen,
Germany) conditions of 94°C for 1 min; 25 cycles of 94°C for 30 sec, 68°C for 4 min; 68°C for
5 min and 15°C soak.
For quantitative PCR, total RNA was extracted from the different cell lines. RNA was
then converted to cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems Inc.
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(ABI), Foster City, CA). qPCR analysis was performed using TaqMan probes for HIF-1α (ABI
Catalog number Hs00936366) or HIF-1α785 (ABI Custom Primer Order) as well as β-actin
(ABI Catalog number 4326315E). The reactions were performed under conditions specified in
the ABI TaqMan Gene Quantitation assay protocol. Data was corrected for efficiency and
loading using the Pfaffl method (Tichopad et al., 2003). Data is representative of at least 3
separate experiments.

DNA constructs
The pLenti-V5-D-TOPO vector was used in gain of function experiments in the SbCl2
radial growth phase human melanoma cells. HIF-1α or HIF-1α785 was cloned into this vector
by amplifying these genes using primers specific for both the 5' and 3' ends of HIF-1α. The
linearized pLenti-V5-D-TOPO Vector contains 5' GTGG overhangs at one end while the insert
is Taq Amplified to contain a 5' CACC overhang at one end. Following amplification, 20 μL of
the 50 μL PCR amplification reactions were separated on a 1% agarose gel stained with
ethidium bromide to ensure that the correct size amplicon was present. HIF-1α and HIF-1α785
amplicons were purified from the remainder of the PCR reaction using the Zymo DNA Clean
& Concentrate Kit® (Zymo Research Inc., Orange, CA). After ligation, plasmids were
transformed into Stbl3 competent cells (Invitrogen Corp., Carlesbad, CA) and plated onto agar
plates containing 100 μg/mL ampicillin. Plates were incubated at 37°C overnight and then
colonies were screened for intact insert in the correct orientation. Plasmids were isolated from
positive colonies and analyzed by DNA sequencing to ensure the correct plasmid expression
construct. Control plasmid, pLenti-V5-LacZ, was supplied in the ViraPower kit® (Invitrogen
Corp., Carlsbad, CA).
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Transient expression studies
SbCl2 cells were transfected at ~80% confluence with either transfection reagent alone
(mock), pLenti-LacZ, pLenti-V5-D-TOPO-HIF-1α, or pLenti-V5-D-TOPO-HIF-1α785 using
FuGene 6 transfection reagent as per manufacturer's protocol (Roche, Palo Alto, CA). After 48
h protein was extracted and overexpression was confirmed by western blot as described above.

siRNA inhibition of HIF-1α
WM9 cells seeded into 6 well plates at 2.0 × 105 were treated 24 h after seeding with
either 100 nM HIF-1α siRNA or 100 nM control non-targeting siRNA (Dharmacon, Inc.
Lafayette, CO) using the RNAifect® transfection reagent (Qiagen, Inc.) as per the
manufacturer's instructions. HIF-1α inhibition was confirmed by western blotting at 48, 72, 96,
and 120 h after transfection. There was ~70% - 80% decrease in HIF-1α protein relative to
control siRNA treated WM9 cells at each time point. Cell viability assays were performed
using WM9 cells transfected with control siRNA or HIF-1α siRNA at 48, 72 and 96 h by the
trypan blue exclusion method.

Matrigel invasion assay
SbCl2 cells overexpressing either HIF-1α, HIF-1α785, or LacZ for 24 h, or WM9 cells
transfected with Control siRNA or HIF-1α siRNA for 48 h were seeded into 6-well Matrigel
(+) chambers, and, as a control, 6-well Matrigel (-) chambers (BD Biosciences) at 7.0 × 104
cells per well. At 24 hours post-seeding, the Matrigel was removed from the chambers using a
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cotton-tipped applicator. After all the Matrigel on the inner part of the chambers was removed,
invading cells were fixed with 80% methanol for 5 minutes and then stained with 0.5% crystal
violet for 5 minutes. After staining, the cells/chambers were extensively washed with distilled
water. Once excess stain was removed, cells were manually counted using a grid system
covering the entire lower surface of the chamber.

Anchorage-independent growth assay
CytoSelect 96 well Cell Transformation Assay® (Cell Biolabs, Inc.) was used to
determine anchorage-independent growth of SbCl2 cells overexpressing either HIF-1α, HIF1α785, or LacZ and WM9 cells transfected with Control siRNA or HIF-1α siRNA. Cells were
seeded at a density of 1.0 × 104 into a 0.4% agar layer poured over a 0.6% agar layer in wells of
a 96 well plate and incubated for 4-5 days as per manufacturer's instructions. Wells lacking
cells served as a fluorescent blank control. Agar layers were solubilized, cells were lysed, and
nucleic acid content stained with CyQuant dye. The amount of Cyquant dye in each well was
determined using a fluorescent plate detector (Molecular Devices' Spectra Max GEMINI EM
Microplate spectrofluorometer; Biocompare Inc., CA) at 485/520 nm. Anchorage-independent
growth of WM9 cells transfected with Control siRNA or HIF-1α siRNA for 5 days was also
confirmed by microscopic examination (20×).

ERK inhibition
WM9 cells were seeded into 10 cm dishes at a density of 5.0 × 105 and the next day were
treated with either 30 or 10 μmol/L U0126 (Promega, Madison, WI), a MEK1/2-specific
inhibitor to block ERK1/2 activation or vehicle (DMSO). ERK inhibition was verified by
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western blotting at 24, 48 and 72 h using both total and phospho-specific ERK antibodies.
WM9 cells seeded into 6 well plates at 2.0 × 105 were treated 24 h after seeding with either 100
nM MEK1 and MEK2 siRNA or 100 nM control non-targeting siRNA (Dharmacon, Inc.
Lafayette, CO) using the RNAifect® transfection reagent (Qiagen, Inc.) as per the
manufacturer's instructions. Both MEK1 and MEK2 inhibition was confirmed by western
blotting at 72 h after transfection. There was ~80 - 90% decrease in MEK1 and MEK2 protein
relative to control siRNA treated WM9 cells at each time point.

Statistics
Statistical analysis of the data was performed using the student paired t test or ANOVA
as appropriate. The statistical test used for each data set is stated in the figure legends; p < 0.05
was considered to be significant. Error bars in all figures represent SEM.
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Abstract
We have previously shown that human melanoma cells express hypoxia factor-1α (HIF1α) under normoxic conditions. Gene expression profiling identified Microphthalmia
associated transcription factor (MITF) as a target gene of HIF-1α produced under normoxic
conditions. Knockdown of HIF-1α significantly reduced the expression of MITF mRNA and
protein in metastatic melanoma cells. We analyzed the expression of MITF-A and –M in
human melanocytes and melanoma cell lines.

MITF-M mRNA was highly expressed in

normal human melanocytes relative to all melanoma cell lines. MITF-A and –M expression
was low in cells established from radial and vertical growth phase melanomas, but MITF-A
was highly expressed in two different cell lines established from metastatic melanomas.
Analysis of these data showed a distinct shift from MITF-M mRNA in melanocytes to
predominantly MITF-A in the melanoma cells. Computer analysis of the MITF-A promoter
revealed two hypoxia response elements. Mutation of these sites decreased MITF reporter
gene activity in melanoma cells expressing high levels of HIF-1α. Chromatin
immunoprecipitation revealed direct in vivo binding of HIF-1α to the MITF-A promoter in
WM9 cells. Decreasing MITF levels using siRNA, resulted in a decrease in the number of
viable WM9 cells. These treated cells also had increased amounts of annexin V and cleaved
caspase 3. Overall our data suggest that MITF is a direct target gene of HIF-1α and its
enhanced expression contributes to the survival of metastatic melanoma.
Keywords: HIF-1α; Microphthalmia associated transcription factor; melanoma; MITF-A;
apoptosis
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Introduction

Melanoma, a malignant tumor arising from melanocytes, is the most aggressive type of
skin cancer and is typically resistant to chemo and radio therapy (Soengas and Lowe, 2003).
Over the past decade, the incidence and mortality of melanoma has increased more rapidly than
any other tumor types. Although significant progress has been achieved in understanding the
mechanism responsible for melanoma development, the key factors that regulate progression of
disease are not yet well defined.
Micropthalamia-associated transcription factor (MITF) is a basic helix-loop-helix
leucine zipper dimeric transcription factor (Hodgkinson et al. 1993). MITF is a master
regulator of melanocyte development and function. It regulates melanocyte development by
inducing genes involved in differentiation such as those genes involved in melanogenesis. It
also contributes to melanocyte cell survival by inducing genes involved in cell cycle
progression and anti-apoptosis (Levy et al., 2006). The MITF family consists of various
isoforms that differ in transcription initiation sites. MITF-A is the largest and the most
ubiquitous form while the MITF-M is missing exon 1 and is selectively expressed in
melanocytes.
Although, MITF modulates melanocyte differentiation, it is found to be amplified in 1020% of aggressive melanoma (Levy et al., 2006). It also has an oncogenic role in human clear
cell sarcoma (Davis et al., 2006). Analysis of MITF expression with melanoma tissue
microarrays, showed it was highly expressed in 10–20% cases of metastatic melanomas. MITF
gene amplification in metastatic melanoma is also associated with a decrease of five year
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survival rate relative to melanomas having normal mitf gene copy number (Garraway et al.,
2005). These findings have generated a hypothesis that MITF when highly expressed leads to
differentiation and pigmentation in melanocytes, at intermediate and low levels leads to
proliferation and invasion in melanoma, while its silencing could promote apoptosis in normal
melanocytes and melanoblasts (Carriera et al., 2006).
Hypoxia-inducible factor-1 (HIF-1α) is a master regulator of O 2 homeostasis in cells. It
consists of a heterodimeric transcriptional complex (HIF-1β and HIF-1α). Oxygen-dependent
regulation is at the post-translational level and results in HIF-1α protein stablilization
(Semenza, 2003). HIF-1α controls over 60 genes involved in many aspects of oncogenesis,
including tumorigenesis, anti-apoptosis, angiogenesis and genetic instability.
Recently we have shown that HIF-1α is expressed in human melanoma cell lines grown
in normoxic conditions. Further, we have found that normoxic expression of HIF-1α increased
as a function of malignant progression (Mills et al., 2009). During the course of determining
whether normoxic expression of HIF-1α stimulated different gene targets compared to hypoxic
expression of HIF-1α we found MITF as a potential target gene of HIF-1α.
The objective of this study was to determine whether MITF is a direct target gene of
HIF-1α. Also, we investigated the MITF isoforms expressed in human melanoma cell lines
isolated from different stages of melanoma progression. Lastly, we determined whether
enhanced MITF expression contributed to human melanoma growth and survival.
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Results

Regulation of MITF by HIF-1α in melanoma cells
HIF-1α protein, a key regulator of oxygen homeostasis, is shown to be highly expressed
in WM9 metastatic melanoma cells under normoxic conditions and our data suggest it
contributes to some of its malignant characteristics (Mills et al., 2009). Subsequently, we used
gene expression profiling to determine if different sets of genes were regulated by HIF-1α
under normoxic vs hypoxic conditions. MITF was identified as a potential target gene of HIF1α under normoxic conditions (data not shown). To confirm these findings, we used siRNA to
knock down normoxic expression of HIF-1α in melanoma cells and examined the expression of
MITF. WM9 cells treated with 100 nM HIF-1α siRNA had only 10-15% of the amount of HIF1α protein found in control cells (Figure 3.1A). The expression of MITF mRNA (Figure 3.1B)
as well as protein (Figure 3.1C) was downregulated in HIF-1α siRNA treated WM9 cells
relative to control. To determine which MITF isoform, -A or –M, was regulated by HIF-1α in
WM9 melanoma cells, we performed quantitative RT-PCR using probes specific for each
transcript. We found MITF-A mRNA levels were downregulated > 50% and MITF–M mRNA
levels were downregulated > 40% in HIF-1α siRNA treated WM9 cells relative to control cells
(Figure 3.1D & E).

These experiments suggest that the normoxic expression of HIF-1α

increases MITF mRNA and protein levels in WM9 melanoma cells.
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Figure 3.1 MITF mRNA and protein is regulated by Hif-1α in human melanoma cells.
(A) WM9 cells were treated with either 100nM HIF-1α or control non-targeting siRNA for
72h and nuclear extracts were analyzed by western blot analysis to detect HIF-1α protein
levels. Total Erk was used as a loading control. MITF mRNA expression was measured in
HIF-1α siRNA treated cells relative to control siRNA treated WM9 cells by semi-quantitative
RT-PCR (B) and MITF protein level were measured by western blot (C). GAPDH was used as
a loading control for both RT-PCR and western blot. HemnLP cell extracts were used as a
positive control for MITF expression. The amount MITF isoforms –A (D) and –M (E) mRNA
in HIF-1α siRNA treated WM9 cells was determined by quantitative RT-PCR as described in
methods. Data was corrected for efficiency and loading using the Pfaffl method (Trichopad et
al., 2003). Data is expressed as fold change, corrected for 18S, relative to control siRNA
treated cells. * P value < 0.01

MITF expression in melanoma cells
Although, MITF is known to modulate melanocyte differentiation, it is found to be
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amplified in a fraction of melanomas (Levy et al., 2006). The MITF family consists of various
isoforms whose expression patterns are not well defined in human melanoma cells relative to
human melanocytes. In these studies we have examined the expression of MITF isoforms -A
and -M in human melanocytes and various melanoma cell lines representing different stages of
progression. They include the radial growth phase (RGP) Sbcl2 and WM3211, Vertical growth
phase (VGP) WM1366 and WM3248 and metastatic (MM) WM9 and WM239. MITF-A
mRNA levels were decreased in RGP cell lines and tend to increase as melanoma progresses
from RGP to VGP to MM. They are highly expressed in the MM melanoma cell lines WM9
and WM239 relative to normal human melanocytes (Figure 3.2A). In contrast, MITF-M
mRNA levels were high in melanocytes and low in all of the other melanoma cell lines we
tested, irrespective of the stage of melanoma from which the cell lines was established (Figure
3.2B). When the data are expressed as a ratio of MITF-A to –M it clearly shows a shift in the
mRNA expression from MITF-M to –A in melanoma cell lines relative to melanocytes which
had a ratio of only 0.2 (Figure 3.2C). We also examined the expression pattern of total MITF
protein in all these cell lines and found that MITF protein was highly expressed in melanocytes
and down regulated in RGP and VGP melanoma cell lines while expression was elevated in
MM melanoma relative to RGP and VGP cell lines (Figure 3.2D).
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Figure 3.2 MITF-A and -M expression in human melanoma cells. Total RNA was extracted
from HEMn-LP, WM3211, SbCl2, WM3248, WM1366, WM239 and WM9 cells. RNA was
reverse transcribed and quantitative PCR was performed using TaqMan probes directed at
MITF-A (A), MITF-M (B) and 18S. Data was corrected for efficiency and loading using the
Pfaffl method (Trichopad et al., 2003). Data is expressed as fold change, corrected for 18S,
relative to HEMn-LP. (C) The ratio of MITF-A to –M mRNA levels for all cell lines stated
above was calculated using the data obtained from (A) & (B). (D) Nuclear extracts from
HEMn-LP, WM3211, SbCl2, WM3248, WM1366, WM239 and WM9 cells were subjected to
western blotting to detect MITF protein expression. GAPDH was used as a loading control.

HIF-1α binds and transactivates the MITF-A promoter in melanoma cells
To elucidate the underlying mechanism by which HIF-1α regulates MITF expression in
melanoma cells, we performed MITF-A promoter activity assays. The MITF-A promoter

73

region containing two hypoxia response elements (HRE) was cloned upstream of a luciferase
reporter gene as described in the Methods section and then transfected into MM melanoma cell
lines. The MITF-A promoter activity, monitored by luciferase levels was increased by more
than 80 and 20 folds in WM9 and WM239 melanoma cells respectively compared to cells
transfected with the luciferase reporter gene without the MITF-A promoter. When we
decreased HIF-1α expression in WM9 and WM239 cells the MITF-A promoter deriven
luciferase levels were significantly reduced by more than 50% (Figure 3.3B & C).

To

determine whether HIF-1α regulates MITF-A promoter activity through the HRE’s present in
the promoter region of MITF-A, we generated two mutant plasmids Mut1 & 2, containing a
mutated sequence of either one or both of the HRE’s. Transfection of these mutated constructs
into the WM9 cells showed that MITF-A promoter activity decreased relative to WT promoter.
The reduction in Mut2 promoter activity relative to the wild type MITF-A promoter activity
was significantly different (P Value < 0.05) (Figure 3.3D).
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Figure 3.3 MITF-A promoter activity in WM9 melanoma cells. (A) A schematic
representation of the MITF locus illustrates that MITF-A & -M use two different promoters.
MITF-M starts transcription from exon 2 and uses the promoter region between exon 1 & 2
(Davis et al., 2006; Levy et al., 2006). MITF-A uses the promoter region upstream of exon 1
and this region also contains two hypoxia response elements (HRE). The sequence of the
MITF-A promoter region (highlighted grey) containing both HRE (bold) was cloned into a
luciferase reporter plasmid from Panomics. WM9 (B) and WM239 (C) cells were treated with
either 100nM HIF-1α or control non-targeting siRNA. After 24h of siRNA treatment, cells
were subjected to transfection of the luciferase reporter plasmid containing either the MITF-A
promoter or an empty vector. Cells were co-transfected with a β-gal expression plasmid to
correct for transfecion efficiency. At 48h post transfection, cell extracts were assayed for
Luciferase and β-galactosidase activity. Data is expressed as relative fluorescence units (RFU)
and luciferase activity is corrected for β-galactosidase activity. (D) WM9 cells were transfected
with the luciferase reporter plasmid containing either no MITF promoter sequence (Control),
wild type MITF-A promoter (MITF-A WT) or an MITF-A promoter containing a mutation in
the downstream (MITF-A mut1) or mutations in both HRE elements (MITF-A mut2). Cells
were co-transfected with β-gal to correct the transfecion efficiency and 48h post transfection
cell extracts were assayed for Luciferase and β-galactosidase activity. Data is expressed as
relative fluorescence units (RFU) and luciferase activity is corrected for β-galactosidase
activity. * P Value < 0.01 and # P Value < 0.05
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To demonstrate in vivo binding of HIF-1α to the MITF-A promoter region in melanoma
cells, we performed a chromatin immunoprecipitation assay. Chromatin complexes were
immunoprecipitated from WM9 cells by using a CHIP grade HIF-1α antibody and PCR was
performed using specific primers to the human MITF-A promoter region. As shown in Figure
3.4 (upper panel), we detected a specific amplification of the MITF-A promoter region in HIF1α immunoprecipiated genomic DNA sample. There was no or very little amplification
observed in IgG and no antibody samples. To validate our immunoprecipitation technique, we
used an RNA polymerase antibody to immunoprecipitate genomic DNA from WM9 cells as a
positive control and specific primers were used to amplify the human GAPDH promoter
region. We detected a specific amplification of the GAPDH promoter region in the RNA
polymerase immunoprecipitated genomic DNA sample, while there was no amplification
observed in IgG and no antibody samples (Figure 3.4 down panel). Collectively these data
indicate that HIF-1α protein regulates MITF-A promoter activity by directly binding to the
proximal region of its promoter in WM9 melanoma cells.
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Figure 3.4 HIF-1α binds to the MITF-A promoter. Chromatin immunoprecipitations were
performed on extracts from WM9 melanoma cells using a specific anti-HIF-1α antibody and
primers spanning the MITF-A promoter region. Magna ChIPTM G kit (Millipore Billerica, MA)
was used and for more details refer to methods. A control PCR amplification was performed
using genomic DNA from WM9 cells, which showed a 500 bp band corresponding to the
amplification of the MITF-A promoter regions. The lower panel was a positive control for
immunoprecipitation in which human GAPDH promoter region (150bp) was amplified only
when RNA polymerase antibody or DNA input was used while no band was observed in no
antibody or IgG antibody cells.

MITF expression as a cell survival factor in melanoma
MITF was highly expressed in the WM9 human metastatic melanoma cell lines. To
determine whether MITF could be contributing to the biologic properties of these cells, we
knocked down its expression and examined how this affected cell replication. Treatment of
WM9 cells with 100 nM MITF siRNA consistently decreased its expression by ~65% relative
to a control siRNA (Figure 5B & C). Knockdown of MITF expression resulted in a significant
decrease in the number of trypan blue excluding cells relative to control siRNA treated WM9
cells (Figure 5A). These data suggest that MITF could be responsible for cell survival in WM9
melanoma cells. To further define MITF’s role in cell survival, we measured the expression of
the pro-apoptotic markers cleaved caspase-3 and Annexin V. Knockdown of MITF expression
in WM9 cells increased the amount of cleaved caspase-3 (17 & 19 kDa) relative to control
siRNA (Figure 6A). The levels of early (Annexin V+ve / 7-AAD-ve) and late (Annexin V+ve / 7AAD+ve) apoptotic markers were significantly higher in MITF siRNA treated WM9 cells
relative to control siRNA (Figure 6B & C). Overall these data suggest MITF is involved in the
cell survival of WM9 melanoma cells.
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Figure 3.5 Decreased MITF expression in human metastatic melanoma WM9 cells
inhibits cell proliferation and viability. (A) WM9 cells were transfected with control siRNA
or MITF siRNA and cell viability assays were performed by counting number of tryphan blue
excluding cells on 2nd, 4th and 6th day. (B) Knock down of MITF expression in WM9 cells was
confirmed by western blot on the 5th day of post transfection. (C) Densitometric analysis of
MITF protein expression for the western blot showed in (B). # P Value < 0.01 and * P Value =
0.055
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Figure 3.6 Decreased MITF expression in human metastatic melanoma WM9 cells
increases apoptosis. (A) Cytoplasmic extracts from WM9 cells transfected with either control
siRNA or MITF siRNA were analyzed by western blotting for cleaved caspase-3. GAPDH was
used as loading control. WM9 cells transfected with either mock or control siRNA or MITF
siRNA were labeled with annexin V pacific blue and 7-AAD and subjected to flowcytometric
analysis. The percentage of WM9 cells positive for annexin-V and negative for 7-AAD is
defined as early apoptotic, (B) while percentage of WM9 cells positive for both annexin-V and
7-AAD is defined as late apoptotic (C). * P Value < 0.01
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Discussion

HIF-1α is the master regulator of cellular and systemic adaption to hypoxia and controls
the expression of genes that are involved in crucial aspects of tumor biology, including
angiogenesis, glycolytic metabolism and cell survival (Semenza, 2003). HIF-1α protein is
rapidly degraded under normoxic conditions and is stabilized under hypoxia. Recently, we
(Mills et al., 2009) and others (Kuphal et al., 2010) have shown that HIF-1α is expressed under
normoxic conditions in human melanoma cells and its expression increases in cells isolated
from more advanced stages of this disease. Further, we have shown that the normoxic
expression of HIF-1α in human melanoma contributes to its malignant characteristics (Mills et
al., 2009). In an attempt to distinguish genes regulated by HIF-1α under normoxic conditions
compared to hypoxic conditions, we discovered MITF as a candidate gene stimulated by HIF1α. Thus, the major focus of this study was to characterize MITF as a novel, directly
transactivated gene of HIF-1α. Also, we have identified differential expression of MITF-A and
-M isoforms in human melanoma relative to normal human melanocytes.
We demonstrate for the first time that the normoxic expression of HIF-1α regulates
MITF at the transcriptional level and leads to increased expression of MITF mRNA and
protein. Transcription factor binding site analysis of the promoters within the MITF gene
identified two HRE’s upstream of exon 1. These HRE’s were present only in the promoter
region of the MITF-A isoform while no HRE was found in the MITF-M promoter region
located between the first and second exons. This information suggests that MITF-A is the
isoform regulated by HIF-1α. However, quantitative RT-PCR showed mRNA expression of
both isoforms MITF-A and -M decreased when HIF-1α expression was knocked down. It is not
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clear how HIF-1α might also regulate MITF-M. Future experiments will need to test MITF-M
promoter activity in melanoma cells where HIF-1α expression can be experimentally increased
or decreased.
MITF-A promoter activity containing both HRE’s showed increased luciferase activity
in both MM cell lines WM9 and WM239. This activity was significantly inhibited when HIF1α expression was knocked down. When both MITF-A HRE sequences were mutated the
luciferase activity was significantly inhibited. However the degree of inhibition was 33%
compared to a 50% decrease in reporter gene activity when HIF-1α expression was inhibited.
The reason for this could be that the four nucleotides we mutated were not sufficient to
completely block the promoter binding of HIF-1α and the possibility of loose binding still
exists. To obtain maximal inhibition of HIF-1α binding to the MITF-A promoter, a broader
region of the promoter may need to be mutated. Chromatin immunoprecipitation results
showed the direct endogenous binding of HIF-1α to the MITF-A promoter. Collectively these
data provide convincing evidence that MITF-A is a direct target gene of HIF-1α.
MITF is a large family consisting of various isoforms that differ in transcription
initiation sites. MITF-A is the largest and most ubiquitously found isoform while MITF-M is
the smallest and is missing exon one. MITF-M is selectively expressed in melanocytes and its
role in differentiation, pigmentation and melanocytic survival has been documented in many
reports (Levy et al., 2006). MITF expression is variable among melanoma specimens. In some
cases, it was shown to be more highly expressed in early stage relative to late stage melanoma
(Salti et al., 2000; Selzer et al., 2002). However, MITF is reported to be highly expressed in
10-20% of advanced melanoma cases and was associated with decreased survival (Garraway et
al., 2005). Recently, MITF has been identified as a marker in the proliferative signature of
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melanoma cells that were less motile than invasive cells (Hoek et al., 2008). In another study
MITF was identified as an oncogene in melanoma specimens representing a transition point for
tumor progression and metastasis (Riker et al., 2008). Because of these opposing findings,
there is controversy regarding the role of MITF in melanoma development and progression. In
many of these studies the MITF isoforms being measured was not determined. Here, we have
examined the expression of MITF isoforms A and M in melanoma cell lines representing
different stages of melanoma progression relative to melanocytes. Both MITF-A and –M
mRNA are expressed in melanocytes with MITF-M more highly expressed relative to –A.
MITF-A and -M mRNAs are both downregulated in RGP and VGP melanoma cell lines, but
significantly higher expression of MITF-A was found in the metastatic melanoma cell lines.
This pattern of MITF-A expression correlates with the significantly higher normoxic
expression of HIF-1α in these metastatic melanoma cell lines (Mills et al., 2009). MITF-A
mRNA has been shown to be expressed in B16 melanoma cells (Murakami et al., 2007). In the
study documenting mitf gene amplification in 10-20% of metastatic melanomas (Garraway et
al., 2005), the PCR primers used to confirm elevated MITF mRNA expression in the clinical
specimens were not specifically designed to detect the MITF-M isoform and could also detect
MITF-A expression. We speculate that MITF-A mRNA might be expressed from those
melanomas containing amplification of the mitf gene.
MITF regulates melanocyte development, function and survival by modulating the
expression of genes involved in differentiation and cell cycle progression (Levy et al., 2006).
In melanoma, MITF, in addition to targeting genes involved in cycle progression, also
stimulates genes involved in anti-apoptosis and cell motility. In mouse melanoma cells, HIF-1α
is identified as a direct target of MITF and was shown to be involved in pro-survival (Busca et
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al., 2005). In this study, MITF targeting HIF-1α was activated by exogenous stimulation of the
α-MSH/cAMP pathway. This pathway is known to transactivate MITF-M through a cAMPresponse element (CRE) located at promoter region between exon one and two (Price et al.,
1998; Levy et al., 2006). However, MITF-M is not highly expressed nor is the α-MSH/cAMP
pathway exogenously activated in our metastatic melanoma cells. Thus, this information
suggests that MITF-M is not involved in normoxic expression of HIF-1α in our human
metastatic melanoma cell lines.
We found that knock down of MITFexpression in WM9 metastatic melanoma cells led
to a decrease in the number of viable cells. Our subsequent finding that knockdown of MITF
expression resulted in increased annexin V binding and increased amounts of cleaved caspase 3
suggest that the decrease in viable cells was due to an increase in apoptosis. Although, MITF
inhibits melanoma tumor xenograft (Selzer et al., 2002) and cell growth by activating cell cycle
inhibitors INK4 (Loercher et al., 2005) as well as p21CIP1 (Carreira et al., 2005), there is
increasing evidence for its role in cell survival. Recently, MITF has been shown to up-regulate,
the anti-apoptotic gene BCL2 (McGill et al., 2002) and to promote melanoma cell growth by
stimulating CDK2 expression (Du et al., 2004). Targeting MITF through direct injection of
siRNA into tumors drastically reduced outgrowth of B16 melanomas in syngenic mice by
inducing apoptosis (Nakai et al., 2007). This latter study, together with our findings, suggests
that in some melanomas MITF is a pro-survival factor. The fact that decreasing MITF in some
melanoma cells leads to apoptosis is reminiscent of the phenomenon of “oncogene addiction”
(Weinstein, 2002; Weinstein and Joe, 2006). We speculate that the switch from predominantly
MITF-M in melanocytes to predominantly MITF-A in some metastatic melanomas may
contribute to their anti-apoptotic phenotype. In summary we have shown that normoxic
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expression of HIF-1α in more aggressive human melanoma cells activates the direct expression
of the MITF-A gene and that expression of MITF-A contributes to melanoma cell survival. It
will be interesting to determine whether MITF-A has a slightly different set of target genes,
perhaps more in pro-survival pathways compared to MITF-M.
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Materials and methods

Cell lines and cell culture conditions
SbCl2, WM3211 (RGP), WM1366, WM3248 (VGP), and WM9, WM239 (Metastatic
melanoma) cells were a generous gift from Dr. Meenhard Herlyn’s lab at the Wistar Institute
(University of Pennsylvania). All cells were grown in a humidified incubator with 5% CO 2 and
95% air at 37°C. The SbCl2 and WM3211 cells were cultured in MCDB153 media (Invitrogen,
Carlesbad CA) as described in (Mills et al., 2009). WM1366, WM3248, WM9 and WM239 cells
were cultured in RPMI medium (Invitrogen Corp., Carlsbad CA) supplemented with 10% fetal
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bovine serum and 100units/mL penicillin plus streptomycin solution. Normal human
melanocytes (HEMn-LP) were derived from human foreskins (Cascade Biologics, Portland, OR)
and maintained in Medium 254 supplemented with 5mL human melanocyte growth supplements
(HMGS) (Cascade Biologics, Portland, OR) and 1mL PSA solution (Cascade) (Mills et al.,
2009).

Western Blot analysis
Nuclear extracts from each cell line were isolated using the NePER kit® (Pierce,
Rockford, IL) according to the manufacturers protocol. Protein concentration was determined
using the BCA protein assay reagents from Pierce as per the manufacturer’s instructions.
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes using the
BioRAD MiniProtean3® system. Equal loading was also determined by Ponceau staining of the
nitrocellulose membranes. Blots were blocked using 5% non-fat dry milk for 1hr at room
temperature and probed overnight at 4°C with either anti-HIF-1α mouse monoclonal antibody at
1ug/mL (R&D Systems, Minneapolis, MN), 1:1000 p44/42 MAPK (Cell signaling Tech Inc,
Danvers, MA), 1ug/mL MITF (C5) (Abcam, Cambridge, MA), GAPDH (Chemicon, Billerica,
MA), or titer Cleaved caspase 3 (Cell signaling Tech Inc, Danvers, MA). Monoclonal mouse
secondary IgG antibody (GE Healthcare, Piscataway, NJ) or rabbit secondary IgG antibody (Cell
signaling) conjugated with HRP was applied after two 1x TBS + 0.05% Tween (TBS-T) washes.
Blots were incubated with secondary antibody at 1:3000 for 1h at room temperature and
subsequently washed 2x with 1x TBS-T. A final 5 minute wash with TBS (no Tween) was
performed and immunoreactive bands were detected using the ECL system (GE Healthcare,
Piscataway, NJ).
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RNA isolation and RT- PCR
Total RNA was extracted using an RNeasy mini kit (Qiagen, Valencia, CA). The purified
RNA samples were dissolved in RNase-free water and quantitated using a Nanodrop
spectrophotometer (NanoDrop Technology, Inc., Wimington, DE). Each RNA sample had an
A260/A280 ratio of 1.8 or above. The quality of RNA was determined on the Agilent 2100
Bioanalyzer, using the RNA 6000 Nano Assay kit (Agilent Tehcnologies, Wilmington, DE) and
reverse transcribed using the RT-for-PCR kit (Clontech, Palo Alto, CA) as per manufacturer’s
instructions. Primers were designed to amplify only MITF-A. MITF-A primers were designed to
target exon 1, which is absent in MITF-M. The sequences of MITF-A primers were: forward
primers 5’- ATGCAGTCCGAATCGGGGAT -3’, reverse 5’- TGCCCTGTTTTGCTCTTCAA 3’. Primers for the housekeeping gene control GAPDH were included in the Advantage cDNA
kit®. Control primers amplifying a fragment of the control plasmid included in the Advantage
cDNA kit® were used to ensure optimal PCR conditions. PCR was performed using
thermocycler (Biometra Tgradient, Goettingen, Germany) conditions of 94oC for 1min; 29 or
32cycles of 94 oC for 30sec, 55 oC for 30sec, 68 oC 1min; 68 oC for 7min and the PCR product
stored at 4oC.
For quantitative PCR, total RNA was extracted from HEMn-LP, WM3211, SbCl2,
WM3248, WM1366, WM239 and WM9 cells. RNA was then converted to cDNA using the High
Capacity cDNA Archive Kit (Applied Biosystems Inc. (ABI), Foster City, CA). qPCR analysis
was performed using TaqMan probes for MITF-A (ABI Catalog number Hs01115553_m1) or
MITF-M (ABI Catalog number Hs00165156_m1) as well as 18S (ABI Catalog number
4310893E). The reactions were performed under conditions specified in the ABI TaqMan Gene
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Quantitation assay protocol. Data was corrected for efficiency and loading using the Pfaffl
method (Trichopad et al., 2003).

siRNA inhibition of HIF-1α and MITF
WM9 cells were seeded (2.0 x 105 cells/well) into 6 well plates and treated 24h after
seeding with either 100nM HIF-1α siRNA, or 100nM MITF siRNA or 100nM control nontargeting siRNA (Dharmacon, Inc. Lafayette, CO) using the RNAifect® transfection reagent
(Qiagen, Inc.) as per the manufacturer’s instructions. Decreased levels of HIF-1α and MITF
proteins was confirmed by western bloting.

DNA constructs, Transfections and Luciferase reporter assay
The pTL-Luc luciferase reporter vector (Panomics, Affymetrix, Inc. Fremont, CA) was
used in luciferase reporter assay experiments following transfection into WM9 metastatic
melanoma cells. The MITF-A promoter region (Figure 3.3A) was amplified and cloned into this
plasmid

by

using

the

following

AAAAGCTAGCCTTCCTCGTTGTTCCAATCC

–

primers:
3’

and

forward
reverse

5’5’

–

AAAAAGATCTGAGTTTACACTCGCACCCGG – 3’ containing Nhe1 and Bgl2 restriction
enzyme sites that are also present in the pTL-Luc vector. To amplify the MITF-A promoter
region, genomic DNA isolated from WM9 cells was used as a template. Following amplification,
20uL of the 50uL PCR reaction was separated on a 1% agarose gel and stained with ethidium
bromide to ensure the correct size amplicon was present. The remainder of amplified MITF-A
promoter and the pTL-Luc vector were digested with Nhe1 and Bgl2 restriction enzymes and
purified using the Qiagen PCR/DNA kit (Qiagen, Valencia, CA). The linearized pTL-Luc Vector
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and digested PCR product of MITF-A promoter were ligated by the One shot ligation kit (Roche
Applied bioscience. Indianapolis, IN) and then plasmids were transformed into Top10 competent
cells (Invitrogen Corp., Carlesbad, CA) and plated onto LB agar plates containing 100ug/mL
ampicillin. Plates were incubated at 37°C overnight and then colonies were screened for intact
insert in the correct orientation. Plasmids were isolated from positive colonies and analyzed by
DNA sequencing to verify that we had obtained the correct MITF promoter sequence. For
mutation of HRE elements in the MITF-A promoter, we used a site-directed mutational kit
(Strategene, La Jolla, CA) and generated mutant clones as per manufacturer’s protocol. The
mutation

primers

were:

upstream

5,

-

TAAAATAAGCACTTGGACACCCCTCGCAGATGTCTGAGC – 3’ and downstream HRE is
5’ - TGGGAGCTGTAGTTTTACACGGAGCGGCTCCCCAGG – 3’. Mutant 1 (Mut 1) had
only downstream HRE sequence mutated as only one primer i.e., downstream HRE primer was
used while Mutant 2 (Mut 2) had both upstream as well as downstream HRE sequences were
mutated as both upstream and downstream HRE sequences were used.
WM9 cells in 6 well plates were transfected at ~80% confluence with 5ug of pTL-Luc,
pTL-Luc-MITF-A, pTL-Luc-MITF-A Mut1 pTL-Luc-MITF-A Mut2 or mock (no plasmid)
using FuGene 6 transfection reagent as per manufacturer’s protocol (Roche, Palo Alto, CA). 1ug
of pSV-βGal (Promega, Madison, WI) was cotransfected with the reporter plasmids to correct for
transfection efficiency in the reporter assays. Cells were harvested 48h after transfection by
passive lysis buffer (Promega, Madison, WI), incubated for 15min at RT, scraped from the wells
and transferred to microcentrifuge tubes on ice. Cells were centrifuged at 12000xg for 2min at
4oC and the supernatant collected. Cell extracts were assayed for Luciferase and β-galactosidase
activity by appropriate kits from Promega. Luciferase assays were evaluated in the linear range
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and values were normalized to β-galatosidase activity. All transfections were performed in
triplicate dishes and the experiments were repeated three times.

Chromatin immunoprecipitation assay (ChIP)
WM9 cells were grown to ~80-90% confluency in 150mm dishes. For ChIP assay 2x106
cells per ml were used. Chip assay was performed by using Magna ChIPTM G kit (Millipore
Billerica, MA) and the procedure was followed as per manufacture’s instruction. DNA was
crosslinked by treating cells with 1% formaldehyde for 10 min at RT. The reaction was then
neutralized by addition of glycine. Cells were harvested in lysis buffer and chromatin sheared
to 200-1000 base pairs in length by sonication 6 times in 15sec pulses with a rest of 50sec
between pulses.

The sheared chromatin was then immunoprecipitated with or without a

specific monoclonal antibodies to HIF-1α or RNA polymerase. After immunoprecipitation, the
cross-link was reversed by heat treatment (62°C for 2hr and proteinase K digestion). The
captured genomic fragments were then recovered by DNA purification spin columns.
Identification of the captured MITF-A or GAPDH promoter fragments was performed by PCR
analysis using the promoter primers previously described for MITF-A or GAPDH promoter
primers that were provided with the kit. PCR reactions were performed for 30 cycles and the
amplified products were analyzed on a 1% agarose gel.

Cell viability assay
Cell viability assays were performed using WM9 cells transfected with control siRNA or
MITF siRNA at the 2nd, 4th and 6th day post transfection using the trypan blue exclusion method.
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Apoptotic assay
To evaluate for apoptosis, WM9 cells 72h post treatment with mock (no siRNA), control
siRNA (non-targeting sirNA) or MITFsiRNA were trypsinized and pelleted after counting. The
cells were resuspended in 1X binding buffer and 1 x 105 cells were used for the assay. The
cells were stained with annexin-V-pacific blue (Invitrogen Corp., Carlesbad, CA) and 7-aminoactinomycin D (7-AAD; BD Pharmingen, Franklin lake, NJ) as per manufactures instruction
mentioned in Annexin-V Apoptosis detection kit (BD Pharmingen, Franklin lake, NJ). A
minimum of 10,000 events per sample was then acquired on a BD FACS flow cytometer and
data analysis was done using Flow Jo software v.7.5.5 (Treestar, Ashland, OR). The percentage
of WM9 cells positive for annexin-V and negative for 7-AAD was defined as early apoptotic
while the percentage of WM9 cells positive for both annexin-V and 7-AAD was defined as late
apoptotic. In addition, cleaved caspase-3 was also used as marker of apoptosis and was
measured as described under the section on western blotting.

Stastistics
Statistical analysis of the data was performed using the student paired t test or ANOVA
as appropriate. The statistical test used for each data set is stated in the figure legends; p < 0.05
was considered to be significant. Error bars in all figures represent SEM.
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CHAPTER FOUR
OVERALL DISCUSSION AND FUTURE DIRECTIONS

Melanoma is a malignant tumor that arises from melanocytes. Melanoma incidence is
increasing more rapidly than any other type of tumor and accounts for most skin cancer related
deaths (Melanoma Research Foundation). Melanoma if diagnosed early could be treated with
high success rate but in later stages is notoriously resistant to both chemo- and radio-therapy
(Soengas and Lowe 2003). Although, the mechanism responsible for the development of
melanoma is beginning to be elucidated, the factors that play a role in the progression of
melanoma are not yet established.
HIF-1α protein, a key regulator in adapting cells to hypoxia, is known to be degraded under
normoxic conditions and stabilizes only under hypoxia. Upon stabilization HIF-1α
transactivates genes that play a role in angiogenesis, anaerobic metabolism (Semenza 2003)
and other processes which help the cell survive under adverse conditions. Thus, HIF-1α is
thought to be a regulator of cancer progression. In this study we have found that hypoxiaindependent expression of HIF-1α protein in melanoma cells contributes to in vitro malignant
properties. In addition we have found that MITF, a melanocyte specific protein (Levy et al.,
2006), is a novel direct target gene of HIF-1α in melanoma cells and its high expression appear
to play role in melanoma cell survival.
HIF-1α mRNA as well as protein expression increased from RGP to VGP and VGP to
metastatic melanoma cell lines, while it was undetected in normal human melanocytes.
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Normoxic expression has been found in several other non melanoma types of cancer (Tanaka et
al., 2006; Lee et al., 2007). Subsequent to publication of Chapter one (Mills et al., 2009),
another laboratory confirmed the normoxic expression of HIF-1α in malignant melanoma cells
and this expression was associated with an increase in ROS activity (Kuphal et al., 2010). The
major distinguishing factor for normoxic versus hypoxic expression of HIF-1α is that normoxic
regulation is at the transcriptional level, while hypoxic is at the translational level (Semenza
2003). The increase in expression of HIF-1α in melanoma cells from RGP to VGP and VGP to
MM could be an important and essential factor for the progression of melanoma.
We have also found the expression of an mRNA splice variant, HIF-1α785, at higher
levels, relative to full length HIF-1α, in more advanced melanoma cell lines. The HIF-1α785
variant is missing a part of ODD domain due to lack of exon 11 and the protein encoded by this
mRNA is thought to be more stable under normoxic condition in comparison to full length
HIF-1α (Chun et al., 2003; Lin et al., 2004). In non-melanoma cell lines HIF-1α785mRNA
levels were found to be regulated by stimulation of cells with phorbol ester and involved a
redox-dependent ERK1/2 MAPK pathway (Chun et al., 2003). The mechanism responsible for
the increase of spliced 785 isoform of HIF-1α in melanoma is not known. The arginine/serinerich splicing factor protein (ASF/SF2/SFRS1/SR proteins) controls splicing events in various
proto-oncogenes and tumor suppressors frequently modify their cellular activity (Ward and
Cooper 2010). Many SR proteins are up-regulated in number of cancer cell types (Fischer et
al., 2004; Karni et al., 2007). Over expression of SF2/ASF has been shown to transform
immortalized fibroblast cells and these transformants form sarcomas in nude mice (Karni et al.,
2007). In another study SF2/ASF are shown to regulate the switch from the anti-angiogenic
VEGFb isoform to angiogenic VEGF isoform by altering splicing sites (Qiu et al., 2009). Thus,
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such splicing factors could be responsible for the increased expression of the splice variant
HIF-1α785 in melanoma cells.
To further investigate the biological effects of HIF-1α expression on melanoma biology, we
took the approach of gain of function and loss of function studies. In the former case, we
choose a low HIF-1α expressing SbCl2 (RGP) cell line and transiently over expressed HIF1αFL and 785. These cell lines are also known to have limited ability to form soft agar colonies
and to invade through Matrigel. Gain of function studies in low HIF-1α expressing RGP cells
revealed that overexpression of full length and 785 HIF-1α induced a small increase in
anchorage-independent growth, but much larger and statistically significant increase in
matrigel invasion. The smaller increase in anchorage independent growth could be limited by
transient over expression of HIF-1α in RGP cells, which last for not more than 48 hours and
the requirement of this assay is for duration of 5 days. This could be further investigated by
stably expressing HIF-1α in RGP cells and testing their ability to increase anchorageindependent growth. Another explanation could be that HIF-1α alone might not be sufficient,
and other factors or genetic changes are also necessary to acquire anchorage-independent
growth characteristics in RGP cells. The overexpression of stable HIF-1α under normoxic
conditions promotes anchorage-independent growth in melanocytes having an activated AKT
signaling pathway (Bedogni et al., 2008).
RGP cells overexpressing HIF-1α785 splice variant had a slight increase in both soft agar
colony formation and Matrigel invasion relative to full length HIF-1α. This difference might be
due longer half life of the splice variant 785 compare to full length HIF-1α under normoxic
condition (Chun et al., 2003; Lin et al., 2004). Although, the splice variant is thought to be
more stable compared to full length under normoxic conditions, the protein stability of 785 has
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never been investigated. In future I would like to measure the half life of the 785 protein
relative to full length HIF-1α under non-hypoxic condition which we think might be a major
contributor to the total expression of HIF-1α protein in melanoma cells.
In the loss of function study we choose the high HIF-1α expressing WM9 metastatic
melanoma cell line. This cell line has a high ability to form colonies in soft agar and to invade
through Matrigel. Loss of function studies in high HIF-1α expressing metastatic melanoma
cells revealed that loss of HIF-1α significantly diminished their ability to form colonies in soft
agar and to invade Matrigel compared to control cells. HIF-1α regulates genes involved in
invasion and metastasis (Krishnamachary et al., 2003; Luo et al., 2006) which might account
for HIF-1α-mediated Matrigel invasion of WM9 cells. Twist, a developmental protein, is a
master regulator of epithelial-mesenchymal transition that is an essential step required by cells
to invade into the surrounding tissue (Yang et al., 2004). Twist was shown to be a direct target
gene of HIF-1α in head and neck cancer cells and correlates with the higher incidence of
cancer metastasis (Yang et al., 2008). In my microarray analysis, Twist was found to be
regulated by HIF-1α in WM9 cells (data not shown).
The normoxic expression of HIF-1α and its biological role in melanoma progression
described here are based on cell culture studies and these findings need to be translated to in
vivo models. The stable overexpression of HIF-1αFL or its 785 splice variant in RGP cells
should increase the potential of these cells to invade and metastasize when injected in
immunocompromised nude mice. The inducible knockdown of HIF-1α expression in metastatic
melanoma cells should decrease the potential of these cells to invade and metastasize when
tumor bearing mice bearing are treated with the inducing agent. Further, the normoxic
expression of HIF-1αFL and 785 splice variant mRNA could be examined in different stages of
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tumor tissues removed from patient with melanoma. This analysis is complicated, however, by
the probability that certain regions of the tumor may have been hypoxic. These experiments
will further suggest that inhibiting HIF-1α expression might be beneficial in treatment of
melanoma patients.
The dietary component curcumin has been shown to inhibit hypoxia-stimulated in vitro
angiogenesis and to downregulate HIF-1α and VEGF mRNA expression in endothelial cells
(Bae et al., 2006). It will be interesting to test whether curcumin could inhibit normoxic
expression of HIF-1α in melanoma cells. Additional dietary constituents such as quercetin,
epigallocatechin gallate (EGCG), resveratrol, inositol, etc. have been reported to affect HIF-1α
expression or function in different types of cancer cells (Zang et al., 2006; Wu et al., 2008; Gu
et al., 2009) and could be tested to see if they also reduce full length and or 785 HIF-1α mRNA
expressions in melanoma cells.
Hypoxia-independent expression of HIF-1α is thought to be regulated by the ERK-MAPK
and PI3K pathways (Semenza 2003). Most melanomas have constitutively active ERK1/2
MAPK pathway due to mutations in either BRAF or N-RAS (Omholt et al., 2003; Daniotti et
al., 2004). I investigated the involvement of this pathway in the normoxic expression of HIF1α in WM9 cells. When a chemical inhibitor (U0126) at higher concentrations of 30 µM was
used to inhibit the ERK1/2 MAPK pathway, it down regulated the hypoxia independent
expression of HIF-1α in metastatic melanoma cells. However, a lower inhibitor concentration
(10 µM) and more specific approaches, such as siRNA targeting of MEK1 and 2 leading to loss
of ERK1/2 MAPK, did not affect the expression of HIF-1α protein. These results indicate that
the ERK1/2 MAPK pathway is not involved in the normoxic expression of HIF-1α. The initial
downregulation of HIF-1α expression in melanoma cells with higher concentrations (30 µM) of
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chemical inhibitor could be due to off-target effects. This could be further investigated by
determining the involvement of other MAPK’s, such as p38 or JNK, in normoxic expression of
HIF-1α in melanoma cells.
Although a lower concentration (10 µM) of chemical inhibitor did not affect the expression
of HIF-1α in WM9 cells at 24 hours, at the later time points (48 and 72 hours) treated cells had
lower expression of HIF-1α protein. The U0126 compound is unstable in tissue culture media
and produces metabolites that have poor MEK inhibitory activity (Favata et al., 1998). This
information suggests that metabolites of U0126 were responsible for the decrease of HIF-1α
protein at later time points. Future studies are needed to determine the pathway responsible for
the normoxic expression of the HIF-1α gene in melanoma cells. Other than the ERK1/2 MAPK
pathway, the PI3K/AKT pathway is also known to regulate the normoxic expression of HIF-1α
(Semenza 2003). Recently, Kupal and colleagues have hinted at an involvement of ROS and
the NFkB pathway in regulating normoxic expression of HIF-1α in melanoma cells (Kupal et
al., 2010). The AKT pathway is known to regulate the NFkB pathway. The role of these
pathways in the normoxic expression of HIF-1α in melanoma cells needs to be investigated.
In an attempt to distinguish genes regulated by HIF-1α under normoxic conditions
compared to hypoxic conditions, we have found MITF as a potential target gene of HIF-1α.
Thus, the major focus in the second part of my dissertation was to determine whether MITF
was a novel direct target gene of HIF-1α. Also, I have identified the differential expression of
MITF-A and -M in human melanoma cell lines relative to normal human melanocytes.
I have shown for the first time that normoxic expression of HIF-1α regulates MITF mRNA
and protein expression in metastatic melanoma cells. In the process of determining the
underlying mechanism responsible for the regulation of MITF by HIF-1α, I found two hypoxia
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response elements in the MITF-A promoter region (proximal to exon one) while none were
found in the MITF-M promoter region (between exon one and two). As predicted by this
computer analysis, the MITF-A gene is transactivated by HIF-1α in metastatic melanoma cells.
However, quantitative RT-PCR showed that MITF-M as well as MITF-A mRNA were
downregulated when HIF-1α expression was knocked down in WM9 cells. How HIF-1α
regulates MITF-M mRNA levels in WM9 cells is not clearly known. HIF-1α regulation of
MITF-M might involve another transcription factors as an intermediate regulator of MITF-M
promoter. In future experiments MITF-M promoter activity will need to be measured in cells
having altered levels of HIF-1α.
Reporter gene assays showed that HIF-1α regulated the transactivation of an MITF-A
promoter construct containing both HREs transfected into metastatic melanoma cells. Mutation
in these sites reduced the activation of MITF-A reporter gene activity in WM9 cells which
express high levels of HIF-1α. However, the inhibition due to mutations was less than the
inhibition of reporter gene activity when HIF-1α expression was suppressed. The reason for
this could be that the four nucleotides we mutated were not sufficient to completely block the
promoter binding of HIF-1α and the possibility of loose binding to this DNA region still exists.
In addition, HIF-1α is also known to heterodimerize with other bHLH transcription factors
such as myc (Haung 2008). Thus, HIF-1α might be hetero-dimerizing with myc which could be
responsible for the activation of MITF-A gene. Future studies should focus on the role of myc
or other bHLH transcription factors DNA binding sites that might be present in MITF-A
promoter region. Finally, chromatin immunoprecipitation results provided convincing evidence
for the direct in vivo binding of HIF-1α protein to the MITF-A promoter in WM9 metastatic
melanoma cells.
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MITF is a large family consisting of various isoforms that differ in their transcription
initiation sites. MITF-A is the largest and the most ubiquitously found isoform, while MITF-M
is the shortest due to lack of exon one and is selectively expressed in melanocytes. The role of
MITF-M is well documented in melanocytic differentiation, pigmentation and survival (Levy
et al., 2006). MITF is also found to be amplified in 10-20% of advanced melanoma cases and
is associated with decreased survival (Garraway et al., 2005). Although, the MITF-M isoform
has a well-defined role in melanocytes, its roles in melanoma are not yet determined. I
examined the expression of MITF isoforms A and M in melanoma cell lines representing
different stages of melanoma progression relative to melanocytes. MITF-M, is highly
expressed in human melanocytes and downregulated in melanoma cells. However, MITF-A,
while at low levels in early stage melanoma, is highly expressed in advanced metastatic
melanoma cells. This pattern of MITF-A expression correlates with significantly higher
normoxic expression of HIF-1α in these metastatic melanoma cells (Mills et al., 2009).
Expression of these data as a ratio of MITF-M to MITF-A indicates that there is a clear shift in
the expression of MITF-M mRNA in melanocytes to the predominantly MITF-A mRNA
expression in metastatic melanoma cells.
MITF regulates melanocyte development, function and survival by modulating the
expression of genes involved in differentiation and cell cycle progression (Levy et al., 2006).
In melanoma, MITF, in addition to targeting genes involved in cycle progression, also
stimulates genes involved in anti-apoptosis and cell motility. In mouse melanoma cells, HIF-1α
was identified as a direct target of MITF and was shown to be involved in pro-survival (Busca
et al., 2005). In this study, MITF induction of HIF-1α was activated by exogenous stimulation
of the α-MSH/cAMP pathway. This pathway is known to transactivate MITF-M through a
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cAMP-response element (CRE) located at promoter region between exon one and two (Price et
al., 1998; Levy et al., 2006). However, MITF-M is not highly expressed, nor is the αMSH/cAMP pathway exogenously activated in our metastatic melanoma cells. Thus, this
information suggests that MITF-M is not involved in normoxic expression of HIF-1α in our
human metastatic melanoma cell lines. For future studies it will be interesting to determine the
effect knockdown of MITF on the normoxic expression of HIF-1alpha in WM9 cells. This
study will determine whether any positive feedback loop exists which could further stimulate
the expression of HIF-1α via MITF expression in metastatic melanoma cells.
Knockdown of MITF expression in WM9 cells decreased their cell viability. The decrease
in expression of MITF in these cells resulted in an increase in apoptotic markers such as
AnnexinV and cleaved caspase-3. MITF up-regulates the anti-apoptotic gene BCL2 (McGill et
al., 2002) and promotes melanoma cell growth by stimulating CDK2 expression (Du et al.,
2004). Direct injection of siRNA targeting MITF into tumors reduced Bl6 melanoma
outgrowth in syngeneic mice by inducing apoptosis (Nakai et al., 2007). Thus, my data suggest
that the switch from predominant MITF-M in melanocytes to a predominant MITF-A in some
metastatic melanomas may contribute to their enhanced cell survival.
The regulation of MITF-A expression by HIF-1α in melanoma cells could be further
confirmed by determining the levels of MITF-A mRNA when expression of HIF-1α is
increased through ectopic transfection and expression in RGP melanoma cells. RGP cells have
low expression of both HIF-1α and MITF-A. Expressing MITF-A in RGP cells to investigate
its effects on cell proliferation and survival could further define its role in melanoma
development and progression. It will be interesting to determine whether MITF-A has a
somewhat different set of target genes compared to MITF-M. I hypothesize that pro-survival
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genes will be major targets of MITF-A in melanoma cells. Finally, the MITF-A promoter
which is exclusively regulated by normoxic expression of HIF-1α in melanoma cells could be
used in targeted gene therapy. Genetically engineered viral constructs containing a tumor
suppressor gene downstream of the MITF-A promoter could be transfected into the HIF-1α
expressing melanoma cells. The high expression of HIF-1α in melanoma cells would be
expected to transactivate the tumor suppressor gene through the MITF-A promoter leading to
selective inhibition of melanoma tumor growth.
In summary, HIF-1α is overexpressed in melanoma cells under normoxic conditions and
contributes to some of their malignant behavior (anchorage-independent growth and cell
invasion). The expression of a splice variant HIF-1α785, which is missing a part of ODD
domain, was higher in more advanced melanoma relative to full length HIF-1α. Although the
ERK-MAPK pathway was not found to be involved in normoxic expression of HIF-1α, the
PI3K-AKT pathway could be involved and will need to be investigated. In addition, the
normoxic expression of HIF-1α directly transactivates MITF-A gene expression in more
aggressive melanoma cells and the enhanced expression of MITF contributes to melanoma cell
survival (a model illustrating these conclusions is shown in Fig 4.1). This suggests inhibiting
either normoxic expression of HIF-1α or HIF-1α mediated expression of MITF might be
beneficial in treatment of metastatic melanoma.
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Figure 4.1: Model for the expression and function of HIF-1α in normoxic melanoma cell.
In normoxic melanoma cell, HIF-1α protein is found to be expressed at higher levels. These
elevated levels of HIF-1α contributed to some of their malignant properties. A novel HIF1α785 splice variant is also found to be overexpressed in normoxic melanoma cells. The
growth signaling pathways such as ERK-MAPK and PI3K-AKT pathways are thought to be
responsible for the non-hypoxic expression of HIF-1α in growing cells. However, in WM9
cells ERK-MAPK pathway was not found to be involved in the normoxic expression of HIF-1α
and the involvement of PI3K-AKT pathway is need to be investigated. Additionally, the nonhypoxic expression of HIF-1α transactivated MITF-A gene by directly binding to the hypoxia
response elements (HRE) located at its promoter region. The enhanced expression of MITF
contributes to the malignant properties of melanoma cells by increasing their cell survival.
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